Categories
Report

VIVO

*Sponsored by VivoPower PLC

Logo

‍

VivoPower has an existing operational and cash-generative datacenter in Mo i Rana, Norway, to be converted into an AI facility

VivoPower is an independent Nordic focused sovereign AI digital infrastructure provider with it’s anchor asset in Mo i Rana underpinning its Nordic value creation plan

The Nordics is a globally competitive region for data centers

Read the Investor Presentation HERE

______________________________________

Hello Everyone,

The emergence of artificial intelligence has triggered one of the largest infrastructure expansions in decades. As models have scaled and adoption has moved beyond research settings into widespread commercial and government use, the bottlenecks limiting AI growth have shifted away from algorithms and processors toward the powered land underneath them. This shift has elevated powered land to one of the most critical components in the data center supply chain. Powered land refers to a real estate asset with confirmed, deliverable access to utility-scale electrical power, along with the entitlements, grid interconnection, and permits needed for construction. It marks the distinction between an empty plot and a site genuinely capable of supporting a data center. In a market where electricity supply increasingly dictates where capacity can be built and how fast it can come online, powered land has emerged as a fundamental building block of value in the industry.

Turn your attention to VivoPower (Nasdaq: VIVO).

VIVO develops and operates infrastructure that enables sovereign nations and institutional partners to secure control over power, data, and national intelligence, supporting AI, compute-intensive workloads, and energy transition use cases. Their solutions are designed to operate at industrial scale, underpinned by renewable energy, long-duration power access, and infrastructure-grade execution.

Asset-Light Operating Approach: The company holds a position at the front end of the AI data center supply chain. Instead of building and running IT infrastructure itself, it aims to create value through land acquisition, power sourcing, and extended-term lease agreements. We believe this approach offers exposure to growing AI infrastructure needs while limiting technology and operational risk.

Presence in Favorable Power Regions: The company targets markets with inexpensive renewable power and quick grid interconnection timelines. In particular, the Nordic region offers plentiful hydropower with electricity rates under $0.05/kWh, while the Middle East is seeing rising demand for digital infrastructure fueled by national AI programs.

Live Facility Delivers Near-Term Revenue: VivoPower has built up a pipeline of roughly 182 MW of finished or contracted capacity spanning Norway and the UAE. Its Mo i Rana site in Norway is the only facility currently running, with 41.5 MW of live capacity generating income through hosting third-party Bitcoin mining and taking part in grid ancillary service programs. This asset is expected to serve as a revenue foundation as leadership works toward AI-related growth.

Valuation Grounded in Delivery: At present, VIVO stock is priced at 0.9x enterprise value against our projected 2028 EBITDA of $121.0 million, a steep discount to the peer group average of 11.0x. Our $10 price target is based on a 5.5x EV/2028 EBITDA multiple and a fully diluted share count of 62.6 million. We note that this valuation carries speculative risk and depends on management hitting its stated projections, milestones, and build-out schedule for the Mo i Rana site.
‍

Investment Highlights

Swing Towards Positive EBITDA – With the closing of the Norway data center acquisition, the company expects to generateroughly $31 million in revenue and $10 million in EBITDA. The company is also expected to generate an additional $1.9 millionin annual EBITDA in Statnett’s reserve markets in Norway.

Substantial Energized Pipeline – The company has approximately 182MW of completed or secured capacity, anchored by itsoperating 41.5MW Mo i Rana site in Norway, which has pending approval for an additional 40MW, as well as a 100MW site inthe UAE.

Low-Cost Energy Edge – The flagship Norway site uses 100% renewable hydroelectric power and has access to costs below$0.035/kWh.

Capital-Light Model – VivoPower’s operating model is a brick-and-mortar property development strategy, in which it generatesrevenue from development and leases to tenants under long-term contracts.

Strategic Backing – The company is supported by a base of long-term strategic shareholders, enabling it to fund and pursueits AI infrastructure initiatives.

Notice the company’s front-end placement within the data center landscape. Rather than installing or managing IT equipment, VivoPower concentrates on sourcing, entitling, energizing, and building out powered-shell sites that are rented to hyperscalers, sovereign entities, and other large-scale computing users through extended-term agreements. This approach delivers exposure to demand for foundational AI infrastructure while limiting exposure tied to technology upgrade cycles, equipment usage rates, and daily data center management.

The believe the company’s holdings of roughly 182 MW of finished or contracted capacity across Norway and the UAE serve as a key competitive edge, especially as power access increasingly limits new construction worldwide. Availability of inexpensive renewable energy in Nordic markets, with electricity costs under $0.05 per kilowatt-hour, paired with government-fueled demand in the Middle East, could bolster both tenant interest and long-term property values. Consequently, the holdings offer exposure to markets marked by advantageous energy pricing, supportive regulation, and growing demand for AI and data localization capacity.

The holdings are centered on the Mo i Rana site in Norway, the company’s sole functioning asset, purchased in April 2026 for roughly $41 million. The facility currently holds 41.5 MW of live capacity fueled by low-cost renewable hydropower, with an additional 40 MW of growth capacity ready for future buildout. The site presently earns income through a deal with a Bitcoin mining tenant that blends fixed infrastructure fees with a share of mining proceeds via profit-sharing terms and involvement in Norway’s supplementary grid services markets. Per leadership’s projections, the facility should produce roughly $31 million in yearly revenue and $10 million in adjusted EBITDA under its present operating structure, delivering a steady cash flow foundation as the company pushes forward with its AI infrastructure plans.

The current Bitcoin mining agreement is expected to run through June 2027, at which point leadership plans to shift the site’s 41.5 MW of live capacity toward AI and high-performance computing uses. Additionally, the company has noted it is in late-stage talks with prospective AI tenants. Per management’s projections and goals, this stage should generate roughly $70 million in yearly revenue and upwards of $60 million in yearly EBITDA. Leadership also plans to build an additional 40 MW AI-ready facility using the site’s growth capacity. Once the full 81.5 MW AI campus is finished, currently slated for mid-2028, management projects yearly revenue and EBITDA of approximately $140 million and $130 million, respectively.

VivoPower’s Sustainable Competitive Advantage are Strategic Land and Low-cost Power

Developing digital infrastructure assets for AI-ready data centers, including land permitting and energization, design and build to white space for Tier-1 customers such as sovereign nation AI companies and hyperscaler companies like Google, Microsoft, and Amazon.

Durable key competitive advantages relative to publicly traded peers with multi-Bn-dollar valuations:

  • Land secured and energized between $50-$500k/MW in strategic business-friendly and renewable energy-abundant locations, including Nordic countries and the Middle East
  • Access to brownfield land priced substantially below market
  • Secured low-cost renewable power at sub 5¢ per kWh
  • Long-duration power contracts to Triple A-rated tenants
  • Control large powered land portfolios with no GPU delivery and margin compression risks
  • Unit economics results in recycling of capital every 18 months

As global demand for AI and compute-intensive workloads accelerates, the constraints to growth are land and energy, which are at the core of VivoPower’s portfolio strategy.

VivoPower Becomes a Bricks & Mortar Growth Business with a High Reinvestment Rate of Return

‍

NEWS

Jul-20-26 09:36AM

VivoPower announces appointment of Group Finance Director

(Proactive)

09:00AM

VivoPower Appoints Group Finance Director

(GlobeNewswire)

Jul-15-26 11:23AM

VivoPower positions for scarcity of renewable-backed AI compute sites

(Proactive)-6.37%

01:00PM

Noble Capital Markets Initiates Equity Research Coverage on VivoPower

(GlobeNewswire)-13.00%

11:00AM

VivoPower earns Outperform rating as Noble bets on “power-first” AI strategy

(Proactive)

Jul-06-26 03:33PM

VivoPower eyes potential earnings boost from battery storage at Norway data center

(Proactive)

03:00PM

VivoPower Targets Up To USD$4 million Incremental Annualized EBITDA from Battery Energy Storage Integration at Norway Data Center

(GlobeNewswire)

07:59AM

VivoPower’s AI data centre strategy explained – One2One Investor Forum

(Proactive)

08:32AM

VivoPower sharpens AI data center focus, updates separation plans for two units

(Proactive)

Jul-02-26 05:25PM

VivoPower Reinforces Focus on AI Data Center Business and Provides Update on Non-Core Businesses

(GlobeNewswire)-5.65%

Jun-29-26 08:35AM

VivoPower selects preferred tenant for Norway AI data center

(Proactive)-7.45%

07:49AM

Correction: VivoPower Selects Global AI Industry Leader as Preferred Tenant for Lease of Norway Operational Data Center

(GlobeNewswire)

07:39AMLoading…07:39AM

VivoPower Selects Global AI Industry Leader as Preferred AI Tenant for Lease of Norway Operational Data Center

(GlobeNewswire)

‍

MANAGEMENT

SINCERELY,

DISCLAIMER

MicroCapAlerts.io is owned by Dedicated Investors, LLC who is a publisher (the “Publisher”) of favorable information (the “Information”) about publicly traded companies (collectively the “Issuers”) listed on the NASDAQ Stock Exchange (“NASDAQ”), New York Stock Exchange (“NYSE”) and the OTC Markets is a paid advertisement. The Publisher lists its specific compensation at the bottom of this Disclaimer.

The Persons who pay us (“Paying Party”) to publish the Information and their affiliates may hold and control a significant amount of the public float and believe that if potential investors receive favorable information about the Issuers, investors will purchase the Issuers’ shares, including the shares that the Paying Party wants to sell.  The Information is neither a solicitation to buy nor an offer to sell securities. The Information is not intended to be used as a source of information for making an investment decision. The Information is not intended and should not be used for trading or investment purposes.  

Because the Publisher is paid to disseminate the Information to the public, the Publisher is required by the securities laws, including Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose certain information to you regarding its compensation, including the nature and amount of compensation. The Paying Party and its affiliates may engage in buying and selling of the Issuers’ securities before, during and after the Publication of the Information.

The Information provides de minimis information about the Issuers and is only a brief favorable snapshot of the Issuers subject to the Information. The Information consists of only positive content and does not include any negative information about the Issuers whatsoever; accordingly, you should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. The Publisher is not liable for your use of the Information or any success or failure that is directly or indirectly related to your use of the Information, including misinformation, omissions, errors or delays in providing or updating the Information, or for any actions taken by third parties in reliance upon the Information.

The Publisher is not objective or independent, and its publishing of the Information involves actual and material conflicts of interest, including: (i) the Publisher is paid to publish favorable information about the Issuers; (ii) the Publisher does not publish negative information because it is not paid to do so; and (iii) the Publisher is paid to publish the (favorable) Information about the Issuers advising others, including you, to purchase the Issuers’ securities; and while doing so, the Paying Party may plan to sell their shares of the Issuers.

The Information published by the Publisher may recommend that investors buy the Issuers’ shares while the Paying Party and/or their affiliates sell their shares of the Issuers. When the Paying Party sells their shares, the Issuers’ stock price may decline and thereby dramatically reduce the price at which investors can sell their shares. As such, investors who purchase the Issuers’ shares during the Publication of the Information will likely pay inflated prices. The Paying Party may sell the Issuers’ securities for less than the target prices set forth in the Information. The Paying Party and its affiliates may make substantial profits by selling their securities during the Publication of the Information while investors experience losses.  

The Publisher makes no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability, and disclaims, expressly and impliedly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the information is at your own risk.  The Information is provided “as is” without any warranties of any kind without limitation. The Publisher does not verify or confirm any portion of the Information and does not conduct any due diligence or research on any aspect of the Information, including the completeness, accuracy, truthfulness or reliability of the Information.  

Investors should not rely upon the Information for any purpose and should contact a licensed investment advisor and their legal advisor and review all documents about the Issuers with the assistance of such advisors, including documents publicly filed on www.sec.gov and http://www.OTCMarkets.com  to obtain information about the Issuers.

Before investing in any public company, you should conduct your own in-depth investigation with the assistance of your legal, tax and investment advisors of the Issuers’ financial condition, operations, management, products or services, trends in the industry, the Issuers’ trading history, short sale positions and risks that may be material to its business and other information you and your advisors deem material to an investment decision. This investigation should include, but not be limited to, a review of available public sources and information you receive directly from http://www.OTCMarkets.com  and www.sec.gov.

The Publisher is not and does not act in the capacity of any of the following and is not qualified to do so; as such, you should not construe the Publisher’s activities as involving any of the following:

▪ An independent advisor or consultant;

▪ Providing investment advice or acting in the capacity of an investment adviser or engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;

▪ Broker-dealer activities or acting in the capacity of a registered representative or broker;

▪ Stock picker;

▪ Securities trading expert;

▪ Securities researcher or analyst;  

▪ Financial planner or financial planning;

▪ Provider of stock recommendations;

▪ Provider of advice about buying and selling or holding recommendations as to specific securities; or

▪ Making an offer or sale of securities or solicitation to purchase securities.

An investment in the Issuers involves a high degree of risk and uncertainties and may be subject to extreme volume and price volatility, especially during the Publication of the Information.  Favorable past performance of the Issuers does not guarantee future results. If you purchase the securities of the Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Issuers include but are not limited to the risks stated below.

▪ The Information is not a solicitation or recommendation to buy, sell or hold securities, and the Publisher does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. The Publisher conducts no due diligence or investigation of the Information or the Issuers and does not receive any verification from any party regarding the Information.

▪ If the Publisher publishes any percentage gain of the Issuers’ share from the previous day’s close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.  

▪ The Information may contain statements that Issuers’ stock price has increased over a certain period of time, which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon such information in your analysis of the present or future potential of the Issuers or its securities.

▪ The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Issuers’ future stock price or future financial performance.

▪ You may encounter difficulties determining what, if any, portions of the Information are material or nonmaterial, making it all the more imperative that you conduct your own independent investigation of the Issuers and its securities with the assistance of your legal, tax and financial advisor.  

▪ If the Information states that its securities are consistent with the future economic trends or even if your independent research indicates as such, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that Publisher is unable to predict; (c) human and social factors may outweigh future economic trends that Publisher states may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in such economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of fully new circumstances and situations in which uncertainty becomes reality rather than of predictive economic quality; or (f) if the trends involve a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.

▪ The Information contains forward-looking statements, i.e., statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as expects, will, anticipates, and estimates; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Issuers with the assistance of your lawyer, tax advisor and investment advisor as well as any such forward-looking statements. Any forward-looking statements made in the Information are limited to the time period in which they are made, and the Publisher does not undertake to update forward-looking statements that may change at any time.  

▪ The Information is presented only as a brief snapshot of the Issuers and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Issuers and its securities and to consult your financial, legal or other advisor(s) and avail yourself of the filings and information that may be accessed at www.sec.gov or other electronic medium, including: (a) reviewing Information and Disclosure Statements and unaudited financial reports filed with the www.otcmarkets.com; (b) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (c) investment guides at www.sec.gov and www.finra.org.  You should always be concerned that the Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative signs at otcmarkets.com. You should only invest with the assistance of your attorney, lawyer and tax advisor after they have conducted exhaustive due diligence on the particular Issuer and its trading activity.

▪ The Publisher may hire third-party service providers and stock promoters to electronically disseminate live news about the Issuers, yet the Publisher has no control over the content of and does not verify the information that these service providers publish.

The Publisher or its officers, directors, owners, managers, affiliates and control persons were paid to publish the Information about the issuers identified below:

Name of Issuer: 3rd party on behalf of VivoPower PLC

Amount of Cash Compensation: thirty thousand usd

Period of Publication of Information: One day campaign beginning and ending on July twenty third twenty twenty six

Where Information is Published: MicroCapAlerts.io Website, Email Campaign, SMS Campaign, Social Media including but not limited to: Youtube, X, Tiktok, Instagram, Stock Twits, Reddit, Discord.

By reading the Information and visiting the Platform, you agree you have not relied on the Information and agree to indemnify, defend and hold the Publisher harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to your receipt of the Information without limitation.

‍

‍

‍

Categories
Report

VBIO

*Sponsored by Valion Bio, Inc

A late-stage, highly de-risked TLR5 platform with a non-dilutive government funding pathway, a vertically integrated manufacturing subsidiary, and multiple near-term value-inflecting catalysts  

Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model

Read the Investor Presentation HERE

______________________________________

Hello Everyone,

There’s a biotech company betting that medicine has been looking in the wrong place. For decades, drug developers have poured resources into the adaptive immune system — antibodies, T-cell therapies, checkpoint inhibitors — while largely ignoring the body’s original defense mechanism: innate immunity, the system that senses danger within minutes and mobilizes before anything else kicks in.

Valion Bio thinks that gap is the opportunity.

The company’s entire pipeline runs through a single molecule, Entolimod, a Toll-like Receptor 5 agonist now in clinical development. Rather than chasing dozens of programs, Valion is going deep on one well-understood mechanism and testing it everywhere the biology suggests it could matter — from Acute Radiation Syndrome to oncology supportive care to early immuno-oncology work.

What sets Valion apart isn’t just the science, though. It’s the infrastructure around it. Through Velocity Bioworks, a wholly owned manufacturing subsidiary in San Antonio, the company controls its own domestic supply chain and generates commercial revenue independent of its clinical pipeline — a level of self-sufficiency most clinical-stage biotechs simply don’t have. And its closest partners aren’t typical biotech collaborators: BARDA, NIAID, DTRA, the Department of War, and major oncology centers, the institutions actually on the front lines of the problems Valion is trying to solve.

Entolimod is the world’s most advanced TLR5 agonist — for acute radiation syndrome under the FDA Animal Rule pathway, oncology supportive care, and immuno-oncology. The company acquired a $140M+ de-risked asset including an active IND, FDA Fast Track, and Orphan Drug designation. Its wholly owned CDMO subsidiary, Velocity Bioworks, provides domestic biomanufacturing and a path to non-dilutive revenue.

A TLR5 agonist in clinical development — where innate immunity matters most

Mechanism

Entolimod is a Toll-like Receptor 5 (TLR5) agonist. TLR5 is a pattern-recognition receptor on the surface of immune and epithelial cells that, when activated, triggers NF-kB signaling — a central pathway in the body’s innate immune response.

Activation of this pathway has been shown in nonclinical models to influence multiple biological processes associated with the response to radiation exposure, including modulation of cell survival pathways, support of progenitor cell recovery in affected tissues, and effects on immune cell activity, including NK and T cells.

Entolimod is being investigated across multiple indications where activation of this pathway may support cellular and tissue responses. Each indication will require its own clinical development program and regulatory submissions.

Lead indication: Acute Radiation Syndrome

High-dose radiation exposure — whether from a nuclear incident, a radiological weapon, or an accident at an industrial or medical facility — causes Acute Radiation Syndrome (ARS): a cascade of bone marrow failure, gastrointestinal complications, and epithelial damage.

Entolimod is being developed as a medical countermeasure for ARS under the FDA’s Animal Rule — a regulatory framework designed for treatments where human efficacy trials are not ethical or feasible. The program has received Fast Track and Orphan Drug designations from the FDA. The development program includes nonclinical efficacy studies, clinical safety data, and translational work to support dose selection, and continues to advance toward potential regulatory submission.

In a post-hoc pooled analysis of the RS-23 animal study conducted under the FDA Animal Rule, Entolimod was associated with an odds ratio of 7.9. A 25-hour post-exposure treatment window has been observed in nonclinical models. Note: RS-23 was not accepted by FDA as a pivotal study.

Expanded Indications

Neutropenia is a life-threatening drop in white blood cells that affects a significant proportion of patients undergoing chemotherapy or radiation therapy. Currently approved agents include G-CSF products such as Neupogen and Neulasta, which address multiple clinical contexts including chemotherapy-induced neutropenia, stem cell mobilization, severe chronic neutropenia, and mitigation of damage from ARS.

Entolimod is being investigated for its potential to activate innate immune pathways and support tissue responses to injury. In nonclinical models, this activity has been associated with effects in both hematopoietic and gastrointestinal tissues. The program is in early-stage development for oncology supportive care. The global market for oncology supportive-care therapies is estimated at more than $22 billion.

Lymphocyte exhaustion

Chronic infections and cancers can drive T-cells and other lymphocytes into a state of functional exhaustion — reduced cytokine production, reduced proliferative capacity, and loss of effector function. Entolimod’s ability to activate innate immune signaling offers a mechanistic rationale for restoring immune function in these states.

Immune function in older adults

As people age, immune responses may become less robust and less predictable, which can contribute to increased vulnerability to infection and reduced vaccine responsiveness. Entolimod has been evaluated in a Phase 2 study at Mayo Clinic in healthy older adults receiving influenza vaccination. These data support continued exploratory research into the potential effects of TLR5 activation on age-related immune function.

Chronic Radiation Syndrome

Chronic Radiation Syndrome results from prolonged, lower-dose radiation exposure — a clinical condition distinct from ARS and without effective treatment. Entolasta, a second-generation follow-on to Entolimod, is being advanced through IND-enabling studies for chronic indications including Chronic Radiation Syndrome.

Domestic biomanufacturing. Vertically integrated. Operating in alignment with applicable regulatory requirements

Velocity Bioworks is Valion Bio’s wholly owned contract development and manufacturing organization (CDMO) — a U.S.-based biomanufacturing facility that supports Valion Bio’s own supply chain and generates independent commercial revenue serving outside clinical-stage biotech clients.

Why it Matters

Most clinical-stage biotech companies depend on third-party manufacturers — a structural consideration in timelines, costs, and supply chain resilience. Velocity Bioworks supports Valion Bio’s own pipeline and operates as a revenue-generating strategic asset.

For federally funded biodefense programs and engagement with federal biodefense agencies, domestic biomanufacturing operating in alignment with applicable regulatory requirements is an important capability. Velocity was built with that standard in mind.

What Velocity Does

Velocity Bioworks operates from San Antonio, Texas, and provides end-to-end support for clinical-stage biologics development and manufacturing, including:

  • cGMP drug substance and cell bank manufacturing.
  • Upstream and downstream process development and optimization.
  • Analytical testing, assay development, and qualification.
  • Quality control and stability testing.
  • Microbial expression systems.
  • Technology transfer and program management.
  • Regulatory compliance support.
Built for speed to clinic

Velocity is structured around a single operating principle: translate defined program goals into scalable manufacturing processes and robust analytical strategies without compromising quality or timeline. The team designs programs to support near-term clinical milestones while meeting every applicable quality and regulatory requirement.

Two assets. Multiple indications. One mechanism.

Entolimod and its second-generation follow-on, Entolasta, together form a pipeline of innate immune modulating therapies being investigated across biodefense, oncology supportive care, and immuno-oncology. More than $140 million has been invested across the platform to date.

Current programs by asset, indication, and stage of development:

TLR5 platform: one receptor, multiple disease states

Targeted activation of the TLR5 receptor drives a coordinated biological response across multiple tissue systems — enabling one mechanism to address multiple clinical indications:

  • Hematopoiesis — bone marrow recovery (neutrophils, platelets).
  • GI protection — intestinal integrity after radiation injury or chemotherapy.
  • NK / T-cell activation — anti-tumor immunity and immuno-oncology combination potential.
  • Anti-apoptotic signaling — cell survival in bone marrow and GI tissues.
  • Endothelial repair — vascular integrity after radiation exposure.
  • Immune modulation — reversing immunosenescence (Mayo Clinic Phase II).

Development milestones

Anticipated development milestones across the next 18 to 24 months include:

  • Initiation of Neutropenia clinical studies (timing subject to IND readiness)
  • Entolasta IND-enabling studies
  • Entolasta drug substance availability (targeted end of 2026)
  • GMP Entolimod for bioequivalence study (targeted 1Q2027)
  • Entolasta pre-IND meeting (targeted 1Q2027)
  • GMP manufacturing validation activities (targeted 2027)

Milestone timing is subject to clinical, regulatory, and operational factors and may change. Entolasta is expected to be treated by FDA as a new molecular entity and will require its own clinical development program and regulatory submissions.

Market context

The TLR5 platform is being investigated across therapeutic areas with significant market potential, including Acute Radiation Syndrome (estimated $5.5B, 5.2% CAGR), Neutropenia and oncology supportive care (estimated $22.3B, 4.8% CAGR), and Immuno-Oncology solid tumors (estimated $120B, 16.3% CAGR). Market estimates are based on industry sources and do not reflect Valion Bio revenue projections.

NEWS

Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model

Apr 23, 2026

Tivic Health Selected to Present Entolimod™ as a Radiation Countermeasure and its Plans for an Oral Transmucosal Program to the Department of War Tech Watch Program on May 7th

Apr 15, 2026

Tivic Receives Formal Request for Information from Ukrainian Ministry of Health Regarding Strategic Stockpiling of Entolimod

Mar 31, 2026

Tivic CEO To Present at the Upcoming Emerging Growth’s April 2026 Virtual Conference

Mar 27, 2026

Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome

Mar 26, 2026

Tivic Reports Full Year 2025 Results

Mar 25, 2026

Tivic Health CEO Letter to Shareholders

Mar 24, 2026

Tivic To Report 2025 Year-End Financial Results Via Conference Call and Webcast on March 25th at 1:30pm PT / 4:30pm ET

Mar 20, 2026

Biotech Veteran Michael K. Handley Named CEO of Tivic Health Systems to Spearhead Strategic Expansion in Biopharma

Mar 4, 2026

Tivic and BARDA Continue Discussions of Entolimod for Acute Radiation Syndrome on March 10

Feb 18, 2026

Tivic, BARDA Discuss Entolimod(TM) for Acute Radiation Syndrome at TechWatch Meeting

Jan 28, 2026

Tivic to Showcase Strategic Pivot and Forward Outlook on Advancing Entolimod(TM) to Commercialization at DealFlow Discovery Conference

Jan 26, 2026

DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week’s Event

Jan 23, 2026

Tivic CEO To Present at the Upcoming Emerging Growth’s January 2026 Virtual Conference

Jan 20, 2026

Tivic Delivers 200x Scale-up in Manufacturing for Lead Drug Candidate Entolimod(TM) And Achieves Reproducible Yields, Potency and Purity

Jan 12, 2026

Tivic Announces Special Webcast To Discuss Its Recent Acquisition of CDMO Assets – Highlighting Near-Term Strategic Potential and Immediate Contributions to Accelerated Drug Development Timelines

MANAGEMENT

‍‍

SINCERELY,

DISCLAIMER

MicroCapAlerts.io is owned by Dedicated Investors, LLC who is a publisher (the “Publisher”) of favorable information (the “Information”) about publicly traded companies (collectively the “Issuers”) listed on the NASDAQ Stock Exchange (“NASDAQ”), New York Stock Exchange (“NYSE”) and the OTC Markets is a paid advertisement. The Publisher lists its specific compensation at the bottom of this Disclaimer.

The Persons who pay us (“Paying Party”) to publish the Information and their affiliates may hold and control a significant amount of the public float and believe that if potential investors receive favorable information about the Issuers, investors will purchase the Issuers’ shares, including the shares that the Paying Party wants to sell.  The Information is neither a solicitation to buy nor an offer to sell securities. The Information is not intended to be used as a source of information for making an investment decision. The Information is not intended and should not be used for trading or investment purposes.  

Because the Publisher is paid to disseminate the Information to the public, the Publisher is required by the securities laws, including Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose certain information to you regarding its compensation, including the nature and amount of compensation. The Paying Party and its affiliates may engage in buying and selling of the Issuers’ securities before, during and after the Publication of the Information.

The Information provides de minimis information about the Issuers and is only a brief favorable snapshot of the Issuers subject to the Information. The Information consists of only positive content and does not include any negative information about the Issuers whatsoever; accordingly, you should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. The Publisher is not liable for your use of the Information or any success or failure that is directly or indirectly related to your use of the Information, including misinformation, omissions, errors or delays in providing or updating the Information, or for any actions taken by third parties in reliance upon the Information.

The Publisher is not objective or independent, and its publishing of the Information involves actual and material conflicts of interest, including: (i) the Publisher is paid to publish favorable information about the Issuers; (ii) the Publisher does not publish negative information because it is not paid to do so; and (iii) the Publisher is paid to publish the (favorable) Information about the Issuers advising others, including you, to purchase the Issuers’ securities; and while doing so, the Paying Party may plan to sell their shares of the Issuers.

The Information published by the Publisher may recommend that investors buy the Issuers’ shares while the Paying Party and/or their affiliates sell their shares of the Issuers. When the Paying Party sells their shares, the Issuers’ stock price may decline and thereby dramatically reduce the price at which investors can sell their shares. As such, investors who purchase the Issuers’ shares during the Publication of the Information will likely pay inflated prices. The Paying Party may sell the Issuers’ securities for less than the target prices set forth in the Information. The Paying Party and its affiliates may make substantial profits by selling their securities during the Publication of the Information while investors experience losses.  

The Publisher makes no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability, and disclaims, expressly and impliedly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the information is at your own risk.  The Information is provided “as is” without any warranties of any kind without limitation. The Publisher does not verify or confirm any portion of the Information and does not conduct any due diligence or research on any aspect of the Information, including the completeness, accuracy, truthfulness or reliability of the Information.  

Investors should not rely upon the Information for any purpose and should contact a licensed investment advisor and their legal advisor and review all documents about the Issuers with the assistance of such advisors, including documents publicly filed on www.sec.gov and http://www.OTCMarkets.com  to obtain information about the Issuers.

Before investing in any public company, you should conduct your own in-depth investigation with the assistance of your legal, tax and investment advisors of the Issuers’ financial condition, operations, management, products or services, trends in the industry, the Issuers’ trading history, short sale positions and risks that may be material to its business and other information you and your advisors deem material to an investment decision. This investigation should include, but not be limited to, a review of available public sources and information you receive directly from http://www.OTCMarkets.com  and www.sec.gov.

The Publisher is not and does not act in the capacity of any of the following and is not qualified to do so; as such, you should not construe the Publisher’s activities as involving any of the following:

▪ An independent advisor or consultant;

▪ Providing investment advice or acting in the capacity of an investment adviser or engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;

▪ Broker-dealer activities or acting in the capacity of a registered representative or broker;

▪ Stock picker;

▪ Securities trading expert;

▪ Securities researcher or analyst;  

▪ Financial planner or financial planning;

▪ Provider of stock recommendations;

▪ Provider of advice about buying and selling or holding recommendations as to specific securities; or

▪ Making an offer or sale of securities or solicitation to purchase securities.

An investment in the Issuers involves a high degree of risk and uncertainties and may be subject to extreme volume and price volatility, especially during the Publication of the Information.  Favorable past performance of the Issuers does not guarantee future results. If you purchase the securities of the Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Issuers include but are not limited to the risks stated below.

▪ The Information is not a solicitation or recommendation to buy, sell or hold securities, and the Publisher does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. The Publisher conducts no due diligence or investigation of the Information or the Issuers and does not receive any verification from any party regarding the Information.

▪ If the Publisher publishes any percentage gain of the Issuers’ share from the previous day’s close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.  

▪ The Information may contain statements that Issuers’ stock price has increased over a certain period of time, which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon such information in your analysis of the present or future potential of the Issuers or its securities.

▪ The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Issuers’ future stock price or future financial performance.

▪ You may encounter difficulties determining what, if any, portions of the Information are material or nonmaterial, making it all the more imperative that you conduct your own independent investigation of the Issuers and its securities with the assistance of your legal, tax and financial advisor.  

▪ If the Information states that its securities are consistent with the future economic trends or even if your independent research indicates as such, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that Publisher is unable to predict; (c) human and social factors may outweigh future economic trends that Publisher states may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in such economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of fully new circumstances and situations in which uncertainty becomes reality rather than of predictive economic quality; or (f) if the trends involve a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.

▪ The Information contains forward-looking statements, i.e., statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as expects, will, anticipates, and estimates; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Issuers with the assistance of your lawyer, tax advisor and investment advisor as well as any such forward-looking statements. Any forward-looking statements made in the Information are limited to the time period in which they are made, and the Publisher does not undertake to update forward-looking statements that may change at any time.  

▪ The Information is presented only as a brief snapshot of the Issuers and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Issuers and its securities and to consult your financial, legal or other advisor(s) and avail yourself of the filings and information that may be accessed at www.sec.gov or other electronic medium, including: (a) reviewing Information and Disclosure Statements and unaudited financial reports filed with the www.otcmarkets.com; (b) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (c) investment guides at www.sec.gov and www.finra.org.  You should always be concerned that the Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative signs at otcmarkets.com. You should only invest with the assistance of your attorney, lawyer and tax advisor after they have conducted exhaustive due diligence on the particular Issuer and its trading activity.

▪ The Publisher may hire third-party service providers and stock promoters to electronically disseminate live news about the Issuers, yet the Publisher has no control over the content of and does not verify the information that these service providers publish.

The Publisher or its officers, directors, owners, managers, affiliates and control persons were paid to publish the Information about the issuers identified below:

Name of Issuer: 3rd party on behalf of Valion Bio, Inc

Amount of Cash Compensation: twenty thousand usd

Period of Publication of Information: One day campaign beginning and ending on July twenty second twenty twenty six

Where Information is Published: MicroCapAlerts.io Website, Email Campaign, SMS Campaign, Social Media including but not limited to: Youtube, X, Tiktok, Instagram, Stock Twits, Reddit, Discord.

By reading the Information and visiting the Platform, you agree you have not relied on the Information and agree to indemnify, defend and hold the Publisher harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to your receipt of the Information without limitation.

Categories
Report

IMNN

*Disseminated on Behalf of Imunon, Inc

Imunon logo

What if your body’s immune system could be taught to fight cancer at the tumor site?

What if your immune system created a vaccine response that protected against infectious diseases without needing a virus or device to deliver it?  

Recent data helped earn FDA Fast Track and Orphan Drug status (US and EU) and is now being tested in OVATION-3, a 500-patient Phase 3 registrational trial with overall survival as the primary endpoint

IMNN Has Less Than 4M in the Float According to Finviz

Hello Everyone,

We have another company that is brand new to our members we want you to research for today’s session. This one has an excitingly low float of under 4 Million shares according to Finviz.

This is not a catalyst to be overlooked. We all know what can happen when these low float Nasdaq listed companies if momentum kicks in.

The merits of the company itself are encouraging as well. We have looked at hundreds of Biotechs over the past 10 years. It is rare to find one that has an active Phase III trial. The results of the studies thus far have been what the company is looking for and the numbers have been in the companies favor as they move forward.

IMUNON (Nasdaq: IMNN) is a clinical-stage biotech tackling one of oncology’s more stagnant corners: frontline treatment for advanced ovarian cancer, a standard of care that hasn’t meaningfully changed in 30-plus years and where no immunotherapy has ever shown a strong survival benefit.

Its approach is TheraPlas®, a non-viral DNA plasmid platform that delivers therapeutic genes straight into tumors. The lead candidate, IMNN-001, encodes IL-12 and is injected directly into the abdominal cavity to turn an immunologically “cold” tumor “hot.” In a randomized Phase 2 trial (OVATION-2), it produced a 14.7-month median overall survival improvement over chemo alone — jumping to 24.2 months in patients also on PARP inhibitor maintenance. That data helped earn FDA Fast Track and Orphan Drug status (US and EU) and is now being tested in OVATION-3, a 500-patient Phase 3 registrational trial with overall survival as the primary endpoint. Dosing began Q3 2025, with full enrollment targeted for roughly Q1 2029.

New preliminary data, from a minimal residual disease (MRD) sub-study of that same Phase 2 program run with MD Anderson and Break Through Cancer, adds another encouraging signal: a lower MRD-positive rate with IMNN-001 (44% vs. 67% control), higher ctDNA clearance (87.5% vs. 62.5%), and a 100% no-evidence-of-disease rate at second-look surgery vs. 56% in control — alongside a clean safety profile, with no cytokine release syndrome or serious immune-related adverse events reported. The catch: this is a tiny readout, just nine patients per arm at the primary endpoint, not statistically powered, and explicitly described as preliminary and directional. The PARP inhibitor subgroup finding is similarly hypothesis-generating rather than randomized. Still, it echoes the OVATION-2 survival signal and adds another data point supporting the bet now riding on OVATION-3 — the trial that will actually determine whether this benefit holds up at scale.

What if your body’s immune system could be taught to fight cancer at the tumor site?

What if your immune system created a vaccine response that protected against infectious diseases without needing a virus or device to deliver it?  

Most of us know DNA as the building block of life. It codes for everything, for all the proteins in our bodies.  

At Imunon, they are pioneering the use of DNA as a therapeutic that codes for proteins which our body then uses to produce medicine where you need it, for as long as you need it.

The IMUNON team is pioneering technologies that provide the foundation for a range of therapeutics for common, difficult-to-treat forms of cancer as well as technologies for the development of DNA vaccines against infectious diseases.

TheraPlas™

TheraPlas™ is a novel, nonviral delivery system for the development of immunotherapies and other anti-cancer nucleic acid-based therapies.

They are bringing it to market focused on aggressive, hard to treat cancers, starting with advanced ovarian cancer.

There are 300,000 new diagnoses of Epithelial ovarian cancer (EOC) per year globally, 20,000 patients in the US alone, with 70% of diagnoses occurring in the late stage and a high recurrence rate.

Their IMNN-001 product is built on the TheraPlas™ platform, and targets the micro-environement of ovarian cancer via local production of safe and durable levels of a powerful anti-cancer immune agent, IL-12.

3D model of a transparent cell

PlaCCine

PlaCCine is a novel platform for the development of nucleic acid vaccines for infectious diseases and cancer that leverages a multivalent approach and non-viral DNA technology to generate a robust humoral immune response as well as a robust and durable T-cell response.

More than 80 pathogenic viruses have been discovered since 1980, but less than 4% have a vaccine commercially available.

That’s where the PlaCCine platform comes in…

Their team is developing an array of prophylactic vaccines, with strong evidence of immunogenicity and durability of protection.

3D model of coronavirus

‍

NEWS

IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification

Jun 23, 2026

IMUNON to Present at the Life Sciences Investor Forum on June 25th

Jun 22, 2026

IMUNON Announces Up to $10 Million Cash Financing

Jun 4, 2026

IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026

IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026

May 5, 2026

IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study

Mar 31, 2026

IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer

Mar 25, 2026

IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026

Mar 24, 2026

IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY

Feb 5, 2026

IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules

Dec 30, 2025

‍

MANAGEMENT

Stacy R. Lindborg, Ph.D.

President, Chief Executive Officer & Board Director

Stacy R. Lindborg, PhD, was appointed President and Chief Executive Officer of Imunon in May 2024.  Dr. Lindborg has served on Imunon’s Board of Directors since June 2021. Dr. Lindborg has nearly 30 years of pharmaceutical and biotech industry experience with a particular focus on R&D, regulatory affairs, executive management and strategy development. She has designed, hired and led global teams, guiding long-term vision for growth through analytics and stimulating innovative development platforms to increase productivity. Prior to joining Imunon, Dr. Lindborg was Executive Vice President and Co-Chief Executive Officer at BrainStorm Cell Therapeutics where she will remain a member of the company’s Board of Directors. At BrainStorm she was accountable for creating and executing clinical development strategies through registration and launch and progressed its novel cell therapy for ALS through a positive Phase 3 Special Protocol Assessment (SPA) study with the U.S. Food and Drug Administration. She interacted frequently with investors and analysts, represented the company in the scientific community as well as with the media, and played an active role in discussions with potential business partners.

Douglas V. Faller, MD, PhD

Chief Medical Officer

Dr. Faller, an internationally recognized oncologist/hematologist and scientist, has nearly 30 years of pharmaceutical and biotech industry experience with a particular focus on clinical R&D, discovery, regulatory affairs, and strategy development. He has worked with small molecules, gene therapies, biologics and cell therapies to address a range of malignant and non-malignant diseases and disorders, including rare and genetic diseases, and neurological and neuropsychiatric disorders. He has extensive experience in early-stage development as well as global late-stage development and world-wide marketing approvals. He has taken molecules (including those discovered in his own academic laboratories) from first-in-human studies in the clinic, through registrational trials, international regulatory approvals and commercial launch. Prior to his position with the Company, Dr. Faller served as Chief Medical Officer of Skyhawk Therapeutics beginning in 2024, where he led the development of splicing modulators for the treatment of oncological and neurological disorders. From 2022 through 2024, he served as Chief Medical Officer of Oryzon Genomics, leading the development of epigenetic-modifying small molecules in oncology and neuropsychiatric disorders, and prior to that role, from 2015 through 2022, Dr. Faller was Executive Medical Director at Takeda Pharmaceuticals, where he led multiple programs in hematologic oncology, solid tumor malignancies and rare diseases, from first-in-human to global registrational trials and post-marketing trials. He was also extensively involved in Business Development for oncology, hematology and rare diseases. Dr. Faller was the scientific founder and CMO/CSO of Viracta Therapeutics, which he joined in 2019 and remained through 2021, after it became publicly traded and launched a pivotal trial of his therapeutic. Dr. Faller is the scientific founder or co-founder of four biopharma companies. Prior to working full-time in the biopharmaceutical industry, Dr. Faller was a professor at Harvard Medical School, and an attending physician at Brigham and Women’s Hospital, Boston Children’s Hospital and Dana-Farber Cancer Institute. He founded and directed the Comprehensive Cancer Center at Boston University, where he also served as the first Grunebaum Professor for Cancer Research, Vice-Chairman of the Department of Medicine, and Professor of Medicine, Biochemistry, Pediatrics, Microbiology, Pathology and Laboratory Medicine. Dr. Faller received a B.S. in biochemistry from the Massachusetts Institute of Technology, an MD from Harvard Medical School, and a PhD from the Massachusetts Institute of Technology in cancer molecular biology.  He has authored more than 300 abstracts, 230 presentations and 375 manuscripts that have been published in peer-reviewed journals. He is certified in Internal Medicine, Hematology and Oncology, and is a Fellow of the American College of Physicians.

Josh Blacher

interim chief financial officer

Mr. Blacher currently serves as Interim Chief Financial Officer of Imunon, Inc. He has been an employee of Danforth Advisors since September 2022, where he has served as interim chief financial officer in a consulting capacity for numerous public life sciences companies. Prior to joining Danforth Advisors, Mr. Blacher served as Chief Business Officer at InMed Pharmaceuticals (Nasdaq: INM) from April 2018 to August 2019, as Chief Financial Officer of Therapix Biosciences (Nasdaq: TRPX) from April 2017 to April 2018, and as Chief Financial Officer at Galmed Pharmaceuticals (Nasdaq: GLMD) from October 2014 to March 2017. Earlier in his career, Mr. Blacher held senior positions at Teva Pharmaceuticals, Deutsche Asset Management, and Morgan Stanley. Mr. Blacher holds a Bachelor of Arts in Economics from Yeshiva University and a Master of Business Administration in Finance from Columbia Business School.

Kristin Longobardi, MBA

Senior Vice President, strategic operations

Kristin Longobardi was appointed Sr. Vice President, Strategic Operations for Imunon in October of 2024. She comes to Imunon with over 25 years of pharmaceutical and biotech experience driving process optimization and efficiency, portfolio management, financial planning and analytics, and operational strategy development. Prior to Imunon, Ms. Longobardi held a variety of leadership positions at Biogen for over 20 years, most recently, Vice President, Quality Operations and Performance responsible for driving global R&D quality and compliance, operational productivity, alliance management, and executional efficiencies. Prior to that, she was a Sr. Director of Business and Financial Operations first for Biogen Clinical Operations and then for all of R&D, spanning from 2009 to 2016. Before then, she was in Corporate Finance at Biogen. Ms. Longobardi began her career as a scientist at Genome Therapeutics working on DNA sequencing and analysis for the Human Genome Project and other microbial pathogens for drug development and diagnostics. Ms. Longobardi received a Bachelor of Science from Bucknell University and an MBA from Babson College.

SINCERELY,

DISCLAIMER

MicroCapAlerts.io is owned by Dedicated Investors, LLC who is a publisher (the “Publisher”) of favorable information (the “Information”) about publicly traded companies (collectively the “Issuers”) listed on the NASDAQ Stock Exchange (“NASDAQ”), New York Stock Exchange (“NYSE”) and the OTC Markets is a paid advertisement. The Publisher lists its specific compensation at the bottom of this Disclaimer.

The Persons who pay us (“Paying Party”) to publish the Information and their affiliates may hold and control a significant amount of the public float and believe that if potential investors receive favorable information about the Issuers, investors will purchase the Issuers’ shares, including the shares that the Paying Party wants to sell.  The Information is neither a solicitation to buy nor an offer to sell securities. The Information is not intended to be used as a source of information for making an investment decision. The Information is not intended and should not be used for trading or investment purposes.  

Because the Publisher is paid to disseminate the Information to the public, the Publisher is required by the securities laws, including Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose certain information to you regarding its compensation, including the nature and amount of compensation. The Paying Party and its affiliates may engage in buying and selling of the Issuers’ securities before, during and after the Publication of the Information.

The Information provides de minimis information about the Issuers and is only a brief favorable snapshot of the Issuers subject to the Information. The Information consists of only positive content and does not include any negative information about the Issuers whatsoever; accordingly, you should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. The Publisher is not liable for your use of the Information or any success or failure that is directly or indirectly related to your use of the Information, including misinformation, omissions, errors or delays in providing or updating the Information, or for any actions taken by third parties in reliance upon the Information.

The Publisher is not objective or independent, and its publishing of the Information involves actual and material conflicts of interest, including: (i) the Publisher is paid to publish favorable information about the Issuers; (ii) the Publisher does not publish negative information because it is not paid to do so; and (iii) the Publisher is paid to publish the (favorable) Information about the Issuers advising others, including you, to purchase the Issuers’ securities; and while doing so, the Paying Party may plan to sell their shares of the Issuers.

The Information published by the Publisher may recommend that investors buy the Issuers’ shares while the Paying Party and/or their affiliates sell their shares of the Issuers. When the Paying Party sells their shares, the Issuers’ stock price may decline and thereby dramatically reduce the price at which investors can sell their shares. As such, investors who purchase the Issuers’ shares during the Publication of the Information will likely pay inflated prices. The Paying Party may sell the Issuers’ securities for less than the target prices set forth in the Information. The Paying Party and its affiliates may make substantial profits by selling their securities during the Publication of the Information while investors experience losses.  

The Publisher makes no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability, and disclaims, expressly and impliedly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the information is at your own risk.  The Information is provided “as is” without any warranties of any kind without limitation. The Publisher does not verify or confirm any portion of the Information and does not conduct any due diligence or research on any aspect of the Information, including the completeness, accuracy, truthfulness or reliability of the Information.  

Investors should not rely upon the Information for any purpose and should contact a licensed investment advisor and their legal advisor and review all documents about the Issuers with the assistance of such advisors, including documents publicly filed on www.sec.gov and http://www.OTCMarkets.com  to obtain information about the Issuers.

Before investing in any public company, you should conduct your own in-depth investigation with the assistance of your legal, tax and investment advisors of the Issuers’ financial condition, operations, management, products or services, trends in the industry, the Issuers’ trading history, short sale positions and risks that may be material to its business and other information you and your advisors deem material to an investment decision. This investigation should include, but not be limited to, a review of available public sources and information you receive directly from http://www.OTCMarkets.com  and www.sec.gov.

The Publisher is not and does not act in the capacity of any of the following and is not qualified to do so; as such, you should not construe the Publisher’s activities as involving any of the following:

▪ An independent advisor or consultant;

▪ Providing investment advice or acting in the capacity of an investment adviser or engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;

▪ Broker-dealer activities or acting in the capacity of a registered representative or broker;

▪ Stock picker;

▪ Securities trading expert;

▪ Securities researcher or analyst;  

▪ Financial planner or financial planning;

▪ Provider of stock recommendations;

▪ Provider of advice about buying and selling or holding recommendations as to specific securities; or

▪ Making an offer or sale of securities or solicitation to purchase securities.

An investment in the Issuers involves a high degree of risk and uncertainties and may be subject to extreme volume and price volatility, especially during the Publication of the Information.  Favorable past performance of the Issuers does not guarantee future results. If you purchase the securities of the Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Issuers include but are not limited to the risks stated below.

▪ The Information is not a solicitation or recommendation to buy, sell or hold securities, and the Publisher does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. The Publisher conducts no due diligence or investigation of the Information or the Issuers and does not receive any verification from any party regarding the Information.

▪ If the Publisher publishes any percentage gain of the Issuers’ share from the previous day’s close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.  

▪ The Information may contain statements that Issuers’ stock price has increased over a certain period of time, which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon such information in your analysis of the present or future potential of the Issuers or its securities.

▪ The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Issuers’ future stock price or future financial performance.

▪ You may encounter difficulties determining what, if any, portions of the Information are material or nonmaterial, making it all the more imperative that you conduct your own independent investigation of the Issuers and its securities with the assistance of your legal, tax and financial advisor.  

▪ If the Information states that its securities are consistent with the future economic trends or even if your independent research indicates as such, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that Publisher is unable to predict; (c) human and social factors may outweigh future economic trends that Publisher states may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in such economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of fully new circumstances and situations in which uncertainty becomes reality rather than of predictive economic quality; or (f) if the trends involve a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.

▪ The Information contains forward-looking statements, i.e., statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as expects, will, anticipates, and estimates; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Issuers with the assistance of your lawyer, tax advisor and investment advisor as well as any such forward-looking statements. Any forward-looking statements made in the Information are limited to the time period in which they are made, and the Publisher does not undertake to update forward-looking statements that may change at any time.  

▪ The Information is presented only as a brief snapshot of the Issuers and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Issuers and its securities and to consult your financial, legal or other advisor(s) and avail yourself of the filings and information that may be accessed at www.sec.gov or other electronic medium, including: (a) reviewing Information and Disclosure Statements and unaudited financial reports filed with the www.otcmarkets.com; (b) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (c) investment guides at www.sec.gov and www.finra.org.  You should always be concerned that the Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative signs at otcmarkets.com. You should only invest with the assistance of your attorney, lawyer and tax advisor after they have conducted exhaustive due diligence on the particular Issuer and its trading activity.

▪ The Publisher may hire third-party service providers and stock promoters to electronically disseminate live news about the Issuers, yet the Publisher has no control over the content of and does not verify the information that these service providers publish.

The Publisher or its officers, directors, owners, managers, affiliates and control persons were paid to publish the Information about the issuers identified below:

Name of Issuer: 3rd party on behalf of Imunon, Inc

Amount of Cash Compensation: twenty two thousand five hundred usd

Period of Publication of Information: One day campaign beginning and ending on July twenty first twenty twenty six

Where Information is Published: MicroCapAlerts.io Website, Email Campaign, SMS Campaign, Social Media including but not limited to: Youtube, X, Tiktok, Instagram, Stock Twits, Reddit, Discord.

By reading the Information and visiting the Platform, you agree you have not relied on the Information and agree to indemnify, defend and hold the Publisher harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to your receipt of the Information without limitation.

Categories
Report

GRML

*Sponsored by Greenland Mines LTD

‍

$30 Million has been invested in theSkaergaard Project since 2000 –One of the largest undeveloped precious metals deposits on the planet — sitting in a U.S.-aligned jurisdiction, independently verified, and trading for fractions of a penny on the dollar

An updated resource estimate (effective July 3, 2026) raised indicated palladium-equivalent metal 31% to 15.0 million ounces and indicated grade 36% to 3.04 g/t PdEq versus 2022 figures, with inferred PdEq metal up 24% to 17.49 million ounces—This sent GRML Flying on Friday!!!

Greenland Mines Ltd. (NASDAQ: GRML) just secured one of the most strategically located rare earth projects in the Western world through a US$35 million agreement with Neo Performance Materials

Greenland Mines now has two world-class projects: the Skaergaard palladium-gold-platinum deposit and the Sarfartoq rare earth project — both in stable, Western-aligned Greenland

Read The Investor Presentation HERE

‍

Hello Everyone,

Greenland Mines (Nasdaq: GRML) is not a speculative exploration play.The gold, palladium, and platinum at its Skaergaard Project in southeast Greenland have already been confirmed through an independent NI 43-101 Technical Report by SLR Consulting. The deposit is known. The metals are there. What the market hasn’t caught up to yet is the sheer scale of what’s sitting in the ground.

The only thing standing between Greenland and the U.S. is Iran. President Trump stated his “Checklist” at the beginning of his presidency or at least it seems that way. He has already stepped in and accomplished many of the stated goals like energy independence, Venezuela, and securing the border. He talked a lot about these issues and then took action. He also talked a lot about Iran and Greenland. With Iran already in progress, Greenland might be next on the menu for Trump once he puts the problems in the Middle East to bed for the time being. If that happens then Greenland and it’s contents will become even more valuable.

GRML just exploded off of it’s 52 week lows last week and jumped 20% Friday on the back of some explosive news for the company.

Greenland Mines Ltd. (NASDAQ: GRML) announced that SLR Consulting has completed the first SEC S-K 1300-compliant Technical Report Summary for its Skaergaard PGM/gold project in Greenland. The updated resource estimate (effective July 3, 2026) raised indicated palladium-equivalent metal 31% to 15.0 million ounces and indicated grade 36% to 3.04 g/t PdEq versus 2022 figures, with inferred PdEq metal up 24% to 17.49 million ounces. Gains stem partly from better geological modeling and partly from higher metal price assumptions (gold at $3,500/oz) — the release doesn’t say how much of each.

The S-K 1300 compliance clears the path toward an Initial Assessment (a PEA-equivalent study). A 2026 field season is underway (drilling, bulk sampling, engineering, environmental/geotechnical work) evaluating open-pit vs. underground scenarios. These remain resources, not reserves — no economic study, no reserves, no production. The company also runs a biotech division (ALS drug program) and has a pending rare-earths acquisition (Sarfartoq), an unusual combination for a single small-cap. The piece lists comparable PGM producers (Impala Platinum, Ivanhoe Mines, Anglo American Platinum/Valterra, Eastern Platinum) purely for context, explicitly not as peers or endorsements.

At July 2026 metal prices, the Skaergaard deposit contains an estimated $51 billion worth of metals in the ground. The entire company is valued at roughly $48.5 million. That gap is the story.

What the Deposit Actually Holds

  • 6.83 million ounces of gold — a meaningful standalone asset at today’s prices, sitting in a politically stable, NATO-aligned territory less than 1,600 km from the U.S. East Coast.
  • 17.15 million ounces of palladium — enough to satisfy 13 to 15 years of total U.S. consumption, according to the company. Right now, 75–80% of global palladium supply comes from Russia and South Africa.
  • 1.37 million ounces of platinum — another metal classified as critical by the U.S. Geological Survey, with supply similarly concentrated in geopolitically sensitive regions.

Greenland Is a U.S. Strategic Priority

The policy conversation around Greenland has moved well past theory. As a self-governing territory of Denmark and a longtime U.S. ally, Greenland sits in a uniquely advantageous position — stable, friendly, close, and resource-rich. Palladium and platinum both appear on the USGS Critical Minerals List, and securing domestic or allied-nation supply of these metals is now a stated federal policy objective.

Palladium is not just an industrial metal. It’s used in missile guidance systems, radar arrays, satellite components, and secure communications infrastructure. Dependence on Russia and South Africa for 75–80% of global supply is a vulnerability the U.S. government has been trying to address for years. A massive, independently verified palladium deposit controlled by an American-listed company in a friendly jurisdiction is exactly what that policy framework is looking for.

Americans have a strong case for being bullish on Greenland because of its geostrategic position, which is arguably one of the most valuable on the planet. Greenland sits at the crossroads of North America, Europe, and the Arctic, effectively acting as a gatekeeper to the North Atlantic and emerging Arctic shipping lanes. As polar ice continues to recede, new maritime routes are opening that could reshape global trade, and Greenland is positioned right along those corridors. From a defense standpoint, it anchors the critical Greenland–Iceland–UK (GIUK) gap, a choke point used to monitor naval activity—especially from Russia—making it indispensable for U.S. and NATO security architecture. It also hosts infrastructure key to missile warning and space surveillance, reinforcing homeland defense in an era of increasingly advanced threats.

Beyond military relevance, Greenland represents a long-term economic and technological opportunity tied to the future of energy and supply chains. The island holds significant deposits of rare earth minerals and other critical resources used in everything from semiconductors to electric vehicles and renewable energy systems. As the U.S. looks to reduce dependence on foreign suppliers—particularly China—Greenland could become part of a more secure, Western-aligned resource base. At the same time, its cold climate and geographic isolation make it attractive for next-generation infrastructure like data centers and advanced computing facilities. While extraction and development remain difficult today, the strategic value lies in the optionality: as technology improves and the Arctic becomes more accessible, Greenland’s importance is likely to increase rather than diminish.

Greenland sits at the intersection of defense, trade, energy, and emerging technologies, and in a world defined by great-power competition and resource security, that combination is rare.

What is truly encouraging is that Greenland is already home to the production of Tens of thousands of ounces of gold annually.

Just over a month ago we saw Klotho Neurosciences rebrand and focus on a 2 pronged approach with the acquisition of Greenland Mines Corp who owns 80% of one of the largest and most significant undeveloped palladium, gold, and platinum deposits in the world.

What They Actually Control

Greenland Mines holds an 80% stake in the Skaergaard Project, with an option to acquire the remaining 20%. The deposit itself has been studied for nearly 90 years — first discovered in 1935, with a major gold-and-palladium discovery following in 1986. Researchers from institutions including Aarhus University, Caltech, and the Geological Survey of Denmark and Greenland have spent decades documenting its structure.

The company is now advancing into the next phase. They’ve engaged WSP Denmark to conduct environmental baseline work, secured an icebreaker vessel for their 2026 field season, and are working toward a Preliminary Economic Assessment. Separately, they’ve outlined plans for a drilling program targeting a doubling of the total resource to approximately 50 million contained ounces across gold, palladium, and platinum — with vanadium and gallium potentially added to the mix.

Located in Southeast Greenland, the Skaergaard Project is one of the largest undeveloped gold (Au), palladium (Pd), and platinum (Pt) deposits in the world, with a total in-situ resource value of approximately $68 Billion1 at February 2026 metal prices.

Through a new drilling and development program, Greenland Mines Ltd aims to double its resource to ~50 million contained ounces of Au, Pd, and Pt, as well as adding vanadium and gallium to its raw critical metals portfolio.

The Skaergaard intrusion is recognized as one of the world’s largest undeveloped resources of gold‑palladium‑platinum, with additional metals that are increasingly important to energy transition, defense application and high‑technology supply chains.

While the project area has benefitted from decades of geological, resource and academic work, historical environmental datasets are relatively limited, making the current, large‑scale baseline program a critical enabler for responsible, long‑life mine development.

Greenland Mines Signs Drilling Contract with Nordisk Fundering for Expanded 2026 Skaergaard Diamond Drilling Program in Greenland

Published

Jun 22, 2026 8:30am EDT

CHARLOTTE, N.C., June 22, 2026 /PRNewswire/ — Greenland Mines Ltd (“Greenland Mines” or the “Company”) (Nasdaq: GRML) announces that it has signed a diamond drilling contract with Nordisk Fundering A/S (“Nordisk Fundering”) in support of the 2026 field campaign at the Company’s 80%-owned Skaergaard precious and critical metals project in southeast Greenland.

Greenland Mines Logo (PRNewsfoto/Klotho Neurosciences, Inc.)

The 2026 drilling campaign is currently expected to comprise approximately 7,500 meters of helicopter-supported diamond core drilling and is designed to support several parallel technical objectives at Skaergaard, including resource-category advancement, the collection of additional metallurgical material and data for the metallurgical and processing program being carried out by GTK Mintec, and geotechnical characterization to support the evaluation of future open-pit development scenarios.

Greenland Mines believes this integrated drilling approach represents an important step in systematically advancing Skaergaard from a large mineral resource toward a more development-ready project supported by upgraded geological, technical, metallurgical, and engineering datasets.

Experienced Arctic driller and integrated 2026 field program

Nordisk Fundering is an experienced Scandinavian drilling contractor with relevant Arctic and Greenland operating experience and a leadership team with decades of experience working in Greenland under remote and demanding northern conditions. The Company also views Nordisk Fundering’s geotechnical drilling background as especially valuable for the current Skaergaard campaign, as a significant portion of the planned drilling is expected to contribute directly to geotechnical and rock-mass characterization in support of future mine planning and potential pit-wall design assumptions.

As currently planned, the field program will operate with three helicopter-portable drill rigs on site, adapted for diamond exploration drilling in the rugged terrain and capable of operating on rock and selected ice‑covered sites within the Skaergaard license area. Greenland Mines has also contracted helicopter support for the campaign and previously secured the icebreaker and accommodation base camp vessel with helicopter platform for the 2026 field season, further strengthening the logistics platform for efficient execution of the program.

The drilling campaign is expected to include a mix of HQ and NQ core drilling in vertical and angled holes, with certain holes targeting areas relevant for future resource conversion work and others focused on gathering the geotechnical and metallurgical information required for mine planning, open-pit evaluation, and support of the larger surface bulk-sample program planned as part of the 2026 season. In parallel with the drill campaign, Greenland Mines is advancing a broader metallurgical and processing workstream at Skaergaard with GTK Mintec, including flowsheet development and test work intended to strengthen the basis for future economic studies.

Bo Møller Stensgaard, President of Greenland Mines, commented:

“Signing the drilling contract with Nordisk Fundering is another important execution milestone for our 2026 Skaergaard campaign. We are bringing together drilling, metallurgy, bulk-sample preparation, logistics and engineering-oriented fieldwork in a coordinated program designed to strengthen the technical foundation of the project and advance Skaergaard toward future open-pit evaluation and broader development studies.”

Planning for the 2026 Skaergaard field season is advancing rapidly, and Greenland Mines believes that securing a capable Arctic drilling contractor with relevant diamond drilling and geotechnical experience materially improves the Company’s ability to execute an efficient and technically valuable program this season.

‍

NEWS


A Greenland Deposit Just Got Its First U.S.-Compliant Resource Report, and the Indicated Grade Jumped 36%

2 days ago

Greenland Mines (NASDAQ: GRML) Reports 31% Increase in Indicated Palladium Equivalent Resource at Skaergaard Project

4 days ago

Greenland’s Palladium Answer Just Got 31% Bigger, and Washington Is Watching

4 days ago

Greenland Mines Reports 36–44% PdEq Grade Uplift and +31% Increase in Indicated PdEq Ounces at its Skaergaard Gold, Palladium, Platinum Project in First S-K 1300 Technical Report Summary

4 days ago

Greenland Mines (NASDAQ: GRML) Secures Australian Patent for Klotho Gene Therapy Platform

Jul 10, 2026

Biotech Division of Greenland Mines Announces Australian Patent Grant for Klotho Gene Therapy Technology for Treatment of Neuromuscular Diseases

Jul 10, 2026

Greenland Mines (NASDAQ: GRML) Accelerates Rare Earth Development at Sarfartoq Project

Jul 8, 2026

A Greenland Precious-and-Critical-Metals Project Just Took a Planning Step Toward Development, With a Roomful of International Experts

Jul 8, 2026

Greenland Mines (NASDAQ: GRML) Adds Two Geologists to 2026 Skaergaard Field Campaign

Jul 7, 2026

Greenland Mines Adds World Class Magmatic Researchers and Greenland Specialists to 2026 Skaergaard Field Campaign

Jul 7, 2026

The West Wants a Critical-Minerals Supply Chain Outside China. One Nasdaq Company Is Trying to Build a Piece of It in Greenland.

Jul 6, 2026

AnorTech and Greenland Mines Close Strategic Share Exchange Transaction

Jun 30, 2026

Greenland Mines (NASDAQ: GRML) Completes Skaergaard Development Planning Workshop

Jun 25, 2026

A Drilling Crew, an Icebreaker, and a Path to an Open Pit at Skaergaard

Jun 25, 2026

Greenland Mines Concludes Three-Day Technical Workshop to Define and Advance Next Phase of Skaergaard Gold and Critical Metals Project Development

Jun 25, 2026

Greenland Mines (NASDAQ: GRML) Is ‘One to Watch’

Jun 24, 2026

Greenland Mines (NASDAQ: GRML) Signs Drilling Contract for 2026 Skaergaard Field Program

Jun 23, 2026

Greenland Mines Signs Drilling Contract with Nordisk Fundering for Expanded 2026 Skaergaard Diamond Drilling Program in Greenland

Jun 22, 2026

Greenland Mines (NASDAQ: GRML) Engages Tetra Tech, GeoSim for Sarfartoq S-K 1300 Resource Update

Jun 18, 2026

Greenland Mines (NASDAQ: GRML) Accelerates Sarfartoq Rare Earths Project Development with Updated S-K 1300 Resource Estimate Program

Jun 18, 2026

‍

MANAGEMENT

Dr. Joseph SinkuleFounder, Chief Executive Officer (CEO), Director and Chairman of the Board

Dr. Sinkule is the company’s Chief Executive Officer (CEO), Founder, and the Chairman of the Board of Directors. He has over 40 years of drug, biologic, and medical device R&D and commercialization experience. This serial entrepreneur is the founder and driving force behind the Company, its growing product portfolio, and its financing strategies. He has personally managed over 8 drug and biotech products successfully through FDA approval to market, 5 medical devices and 8 in vitro diagnostics. He has hired and managed both small and large teams of experienced people in pharma and biotech organizations, and managed contract research organizations (“CROs”) and contract development and manufacturing companies (“CDMOs”), working for large and small clients. After serving in academics and then in industry, Dr. Sinkule has evolved into a successful businessman and entrepreneur. He serves on the Board of two companies, and routinely consults for venture capitalist firms, investment banks, as well as both large and early-stage pharmaceutical and biotech companies.

Mr. Jeffrey LeBlancChief Financial Officer

Mr. LeBlanc has over 20 years of experience in managing financial operations, investing, advising Fortune 500 companies, and launching new ventures. He is the co-founder of Winvest Acquisition Corp. (Ticker: WINV), a special purpose acquisition company. Prior to Winvest, Mr. LeBlanc launched Out of Print, a direct-to-consumer merchandise platform that was acquired by Penguin Random House in 2017. He previously served in investment roles at Greenlight Capital and GE Capital, and started his career at McKinsey and Co. Mr. LeBlanc previously served on the Boards of Riot New Media Group and Books For Africa. He received an MBA from Harvard Business School and a BS in Chemical Engineering from MIT.

Bo Møller StensgaardPresident

Bo is a seasoned executive with over 20 years in mineral exploration and natural resource development across Europe and the Arctic, starting in Greenland geology in 1998. Holding a PhD in economic geology and former Senior Research Scientist at the Geological Survey of Danmark and Greenland, he has led listed and private resource companies, advancing projects from early exploration to exploitation through technical studies, environmental/social impact assessments, permitting, and stakeholder engagement. His expertise includes listed-company leadership, international investor relations, building expert teams, and leveraging extensive networks in business, academia, politics, and the European raw materials ecosystem – gained partly from his senior advisory role at EIT RawMaterials advising on EU policy and funding. This positions him as a strong leader for Greenland Mines Corp, providing credible access to North American and European capital markets and strategic partners.

Dr. Miguel Chillón RodriguezChief Scientific Officer and Consultant

Professor Dr. Chillon is the inventor of the α-Klotho patents and technology know how. He has over 25 years of research experience in several key areas of α-klotho and adeno-associated virus (“AAV”) packaging and gene delivery. Miguel has several associates that work with him to expedite development and further the intellectual properties and scientific publications. He leads the research group on Gene therapy for CNS diseases at Universitat Autonoma De Barcelona and Institucio Catalana De Recerca I Estudis Avancats. Miguel is also the Director of the Viral Vector Production Unit at Vall d’Hebrón Hospital, and serves Chair of the ATMP Platform of European Infrastructure for Translational Medicine

Dr. Shalom HirshmanMedical Advisor and Director

Dr. Shalom Hirschman, M.D. is a preeminent research physician, a clinical medical expert, and entrepreneur in infectious diseases, oncology, and cancer supportive care. He is a key consulting advisor to the Company. As a young man, he served as an intern and resident in medicine at the Massachusetts General Hospital and Harvard Medical School, and then went on to a career in molecular biology and virology research at the National Institute of Health (NIH). During his career in medical research, he interacted closely with several Nobel Prize winners including Drs. Berson and Yalow (Nobel Prize for development of radioimmunoassays). He was recruited to The Mount Sinai School of Medicine and The Mount Sinai Hospital in New York City as Head of the Department of Infectious Diseases, and eventually he also became Vice-Chairman and Chairman of the Department of Medicine at Mount Sinai, where he remained for three decades. He still is asked to consult on difficult diagnostic dilemmas like the recent COVID-19 pandemic.

SINCERELY,

DISCLAIMER

MicroCapAlerts.io is owned by Dedicated Investors, LLC who is a publisher (the “Publisher”) of favorable information (the “Information”) about publicly traded companies (collectively the “Issuers”) listed on the NASDAQ Stock Exchange (“NASDAQ”), New York Stock Exchange (“NYSE”) and the OTC Markets is a paid advertisement. The Publisher lists its specific compensation at the bottom of this Disclaimer.

The Persons who pay us (“Paying Party”) to publish the Information and their affiliates may hold and control a significant amount of the public float and believe that if potential investors receive favorable information about the Issuers, investors will purchase the Issuers’ shares, including the shares that the Paying Party wants to sell.  The Information is neither a solicitation to buy nor an offer to sell securities. The Information is not intended to be used as a source of information for making an investment decision. The Information is not intended and should not be used for trading or investment purposes.  

Because the Publisher is paid to disseminate the Information to the public, the Publisher is required by the securities laws, including Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose certain information to you regarding its compensation, including the nature and amount of compensation. The Paying Party and its affiliates may engage in buying and selling of the Issuers’ securities before, during and after the Publication of the Information.

The Information provides de minimis information about the Issuers and is only a brief favorable snapshot of the Issuers subject to the Information. The Information consists of only positive content and does not include any negative information about the Issuers whatsoever; accordingly, you should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. The Publisher is not liable for your use of the Information or any success or failure that is directly or indirectly related to your use of the Information, including misinformation, omissions, errors or delays in providing or updating the Information, or for any actions taken by third parties in reliance upon the Information.

The Publisher is not objective or independent, and its publishing of the Information involves actual and material conflicts of interest, including: (i) the Publisher is paid to publish favorable information about the Issuers; (ii) the Publisher does not publish negative information because it is not paid to do so; and (iii) the Publisher is paid to publish the (favorable) Information about the Issuers advising others, including you, to purchase the Issuers’ securities; and while doing so, the Paying Party may plan to sell their shares of the Issuers.

The Information published by the Publisher may recommend that investors buy the Issuers’ shares while the Paying Party and/or their affiliates sell their shares of the Issuers. When the Paying Party sells their shares, the Issuers’ stock price may decline and thereby dramatically reduce the price at which investors can sell their shares. As such, investors who purchase the Issuers’ shares during the Publication of the Information will likely pay inflated prices. The Paying Party may sell the Issuers’ securities for less than the target prices set forth in the Information. The Paying Party and its affiliates may make substantial profits by selling their securities during the Publication of the Information while investors experience losses.  

The Publisher makes no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability, and disclaims, expressly and impliedly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the information is at your own risk.  The Information is provided “as is” without any warranties of any kind without limitation. The Publisher does not verify or confirm any portion of the Information and does not conduct any due diligence or research on any aspect of the Information, including the completeness, accuracy, truthfulness or reliability of the Information.  

Investors should not rely upon the Information for any purpose and should contact a licensed investment advisor and their legal advisor and review all documents about the Issuers with the assistance of such advisors, including documents publicly filed on www.sec.gov and http://www.OTCMarkets.com  to obtain information about the Issuers.

Before investing in any public company, you should conduct your own in-depth investigation with the assistance of your legal, tax and investment advisors of the Issuers’ financial condition, operations, management, products or services, trends in the industry, the Issuers’ trading history, short sale positions and risks that may be material to its business and other information you and your advisors deem material to an investment decision. This investigation should include, but not be limited to, a review of available public sources and information you receive directly from http://www.OTCMarkets.com  and www.sec.gov.

The Publisher is not and does not act in the capacity of any of the following and is not qualified to do so; as such, you should not construe the Publisher’s activities as involving any of the following:

▪ An independent advisor or consultant;

▪ Providing investment advice or acting in the capacity of an investment adviser or engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;

▪ Broker-dealer activities or acting in the capacity of a registered representative or broker;

▪ Stock picker;

▪ Securities trading expert;

▪ Securities researcher or analyst;  

▪ Financial planner or financial planning;

▪ Provider of stock recommendations;

▪ Provider of advice about buying and selling or holding recommendations as to specific securities; or

▪ Making an offer or sale of securities or solicitation to purchase securities.

An investment in the Issuers involves a high degree of risk and uncertainties and may be subject to extreme volume and price volatility, especially during the Publication of the Information.  Favorable past performance of the Issuers does not guarantee future results. If you purchase the securities of the Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Issuers include but are not limited to the risks stated below.

▪ The Information is not a solicitation or recommendation to buy, sell or hold securities, and the Publisher does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. The Publisher conducts no due diligence or investigation of the Information or the Issuers and does not receive any verification from any party regarding the Information.

▪ If the Publisher publishes any percentage gain of the Issuers’ share from the previous day’s close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.  

▪ The Information may contain statements that Issuers’ stock price has increased over a certain period of time, which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon such information in your analysis of the present or future potential of the Issuers or its securities.

▪ The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Issuers’ future stock price or future financial performance.

▪ You may encounter difficulties determining what, if any, portions of the Information are material or nonmaterial, making it all the more imperative that you conduct your own independent investigation of the Issuers and its securities with the assistance of your legal, tax and financial advisor.  

▪ If the Information states that its securities are consistent with the future economic trends or even if your independent research indicates as such, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that Publisher is unable to predict; (c) human and social factors may outweigh future economic trends that Publisher states may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in such economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of fully new circumstances and situations in which uncertainty becomes reality rather than of predictive economic quality; or (f) if the trends involve a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.

▪ The Information contains forward-looking statements, i.e., statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as expects, will, anticipates, and estimates; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Issuers with the assistance of your lawyer, tax advisor and investment advisor as well as any such forward-looking statements. Any forward-looking statements made in the Information are limited to the time period in which they are made, and the Publisher does not undertake to update forward-looking statements that may change at any time.  

▪ The Information is presented only as a brief snapshot of the Issuers and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Issuers and its securities and to consult your financial, legal or other advisor(s) and avail yourself of the filings and information that may be accessed at www.sec.gov or other electronic medium, including: (a) reviewing Information and Disclosure Statements and unaudited financial reports filed with the www.otcmarkets.com; (b) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (c) investment guides at www.sec.gov and www.finra.org.  You should always be concerned that the Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative signs at otcmarkets.com. You should only invest with the assistance of your attorney, lawyer and tax advisor after they have conducted exhaustive due diligence on the particular Issuer and its trading activity.

▪ The Publisher may hire third-party service providers and stock promoters to electronically disseminate live news about the Issuers, yet the Publisher has no control over the content of and does not verify the information that these service providers publish.

The Publisher or its officers, directors, owners, managers, affiliates and control persons were paid to publish the Information about the issuers identified below:

Name of Issuer: 3rd party on behalf of Greenland Mines Ltd

Amount of Cash Compensation: fifteen thousand usd

Period of Publication of Information: One day campaign beginning and ending on July twentieth twenty twenty six

Previous Compensation: One or more partners of Dedicated Investors LLC has been previously compensated sixty five thousand usd on behalf of Greenland Mines Ltd.

Where Information is Published: MicroCapAlerts.io Website, Email Campaign, SMS Campaign, Social Media including but not limited to: Youtube, X, Tiktok, Instagram, Stock Twits, Reddit, Discord.

By reading the Information and visiting the Platform, you agree you have not relied on the Information and agree to indemnify, defend and hold the Publisher harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to your receipt of the Information without limitation.

Categories
Report

SRFM

**Sponsored by Surf Air Mobility Inc.

thumbnail

‍

Surf Air Mobility Reports Q1 2026 Revenue Up 9% to $25.6 Million; Beats Its Own Adjusted EBITDA Guidance and Improves Full Year Outlook by 40%

Palantir Expands Its Partnership and Files a 7.4% Stake as Wheels Up Signs On as Launch Customer for Enterprise BrokerOS in a Deal Worth Up to $12 Million

Surf Air Mobility Refinances Its Convertible Debt to Reduce Dilution as Electric Aircraft Demonstrations Take Flight in Hawaii

READ THE FULL Q1 2026 RESULTS HERE

________________________

Hello Everyone,

This next company operates in one of the largest and most structurally outdated industries in America today.

Air mobility and autonomous aviation technology are two of the most powerful forces reshaping modern transportation. The convergence of AI, electric aircraft, and enterprise software is creating enormous opportunities, not just for aviation companies, but for investors who recognize a structural shift before the rest of the market does.

The market behind that shift is massive. The regional air mobility market is projected to expand to $75 to $115 billion globally by 2035, and the global eVTOL aircraft market is forecast to grow from over $5 billion in 2026 to more than $216 billion by 2035, an increase of more than 4,000%.

Yet despite all of that scale, the industry runs on fragmented systems and manual processes. Scheduling, compliance, booking, and charter sales are still stitched together by hand across thousands of operators and brokers. Aviation never had the software consolidation moment that transformed other industries. One company is building it.

The company we are looking at today is constructing something that has never existed before in aviation. An air mobility platform that combines one of the largest commuter airlines in the United States with an AI-enabled operating system designed to run the entire industry, from scheduling to compliance to booking. A platform powered by Palantir Technologies’ (NASDAQ: PLTR) Foundry and AIP. A system built not just for internal use, but for commercial sale across the broader market.

That company is Surf Air Mobility Inc. (NYSE: SRFM). And the past several weeks were the moment its plan clicked into place.

First quarter revenue came in at $25.6 million, up 9% year over year and at the high end of guidance,while the Adjusted EBITDA loss of $12.3 million beat the guided range of a $15.5 to $13.5 million loss. The company improved its full year 2026 Adjusted EBITDA loss guidance by roughly 40% and reaffirmed revenue guidance of $128 to $138 million, representing 20% to 30% growth over 2025. Then Palantir expanded the partnership, filed a 7.4% stake in the company, and Wheels Up signed on as the first enterprise customer for BrokerOS. SRFM is converting its structural advantages into real, accelerating results.

SRFM has some major catalysts in play right now:

• Q1 2026 Revenue at the High End of Guidance, Adjusted EBITDA Beat, Full Year Outlook Improved 40%: Revenue reached $25.6 million, up 9% year over year. The Adjusted EBITDA loss narrowed to $12.3 million, better than the guided $15.5 to $13.5 million loss range. Full year 2026 Adjusted EBITDA loss guidance improved from a prior range of $50 to $40 million to a new range of $30 to $25 million, while revenue guidance of $128 to $138 million was reaffirmed. This is not a story stock waiting on proof. The inflection is on the books.

• Palantir Deepened Its Commitment and Put Real Capital Behind It: On June 29, Palantir announced an expanded partnership with SRFM, committing additional engineering and go-to-market resources to accelerate the commercial rollout of OperatorOS, OwnerOS, and SurfOS Enterprise Solutions. A Schedule 13G filed June 24 shows Palantir now holds 8,248,989 shares of common stock, a 7.4% stake.

• Wheels Up Signed On as the First Enterprise Customer: On June 25, Wheels Up (NYSE: UP), one of the world’s largest private aviation companies, became the launch customer for Enterprise BrokerOS. The two-year firm agreement includes $8 million in subscription fees, with an option for a third year, for total potential software revenue of up to $12 million.

• SurfOS Is Live and Producing Real Numbers: BrokerOS launched commercially in December 2025 with 29 brokers already enrolled. Early internal results showed 32% more bookings for top brokers, 57% faster quote-to-close, and 40% more payments processed on-platform in Q1 2026 versus Q1 2025. OperatorOS remains scheduled for commercial launch in the second half of 2026.

• The Charter Engine Is Showing Up in the Numbers: Surf On Demand revenue jumped 77% year over year to $10.1 million, its highest revenue and highest gross margin quarter since inception, with revenue per flight up 38%. That is the BrokerOS and Powered by Surf On Demand engine translating directly into results.

• Management Is Strengthening the Balance Sheet: On July 1, SRFM refinanced a roughly $46.9 million senior secured convertible note into a new $16.9 million convertible note due 2027 and a new $30 million non-convertible senior secured term note due 2028, a move explicitly designed to reduce future shareholder dilution. The same day, SRFM subsidiaries also received the first disbursement of a new non-convertible $21.6 million asset-backed loan secured by new and existing aircraft, with a second $14 million tranche expected within 30 days, further strengthening balance sheet liquidity.

• Insiders Bought Alongside Institutions: In April, co-founders, officers, and directors purchased roughly $5.3 million of stock as part of a $30 million raise structured to limit dilution, with $15 million of it in non-dilutive aircraft-backed credit.

• Government and Safety Validation: On May 13, SRFM joined the FAA-sponsored Center for Advanced Aviation Technologies (CAAT) Consortium as the first Part 135 passenger operator to do so. In the same quarter, its airline operations completed a Safety Management System a full year ahead of the FAA’s May 2027 mandate, and Surf On Demand earned ARGUS Certified Charter Broker status.

• An Electrification Catalyst With a Massive Market Behind It: Through a strategic partnership with BETA Technologies, SRFM holds a firm order for 25 all-electric ALIA aircraft with options for up to 75 more, and it eliminated up to $100 million in planned capital expenditure from its prior electrification program along the way. A new demonstration program launched in Hawaii on June 26, with Hawaiian Airlines supporting evaluation activities.

• Analyst Coverage Is Building: HC Wainwright rates the stock at Buy, and Stonegate notes SRFM trades at roughly 1.3x forward EV/Revenue versus a peer average near 2.4x.

SurfOS, powered by Palantir. BrokerOS is commercially live with 29 independent brokers enrolled.

‍

Palantir and Surf Air Mobility Expand Partnership to Accelerate the Commercial Rollout of SurfOS

June 29, 2026

Palantir Technologies (NASDAQ: PLTR) announced an expansion of its partnership with Surf Air Mobility (NYSE: SRFM), committing additional engineering and go-to-market resources to accelerate the commercial rollout of OperatorOS, OwnerOS, and SurfOS Enterprise Solutions.

The expansion builds directly on the successful commercial launch of BrokerOS and the recent multi-million-dollar Wheels Up contract. It also lands on top of a Schedule 13G filed June 24, which shows Palantir holding 8,248,989 shares of Surf Air Mobility common stock, a 7.4% stake in the company.

“Private aviation and air mobility are large, growing markets that have historically relied on fragmented systems and manual processes. With Foundry and AIP powering SurfOS, we see a clear opportunity to build and define the central operating system for the future of aviation and air mobility, and our expanded commitment reflects our conviction in Surf Air Mobility and the opportunity ahead.” – Palantir’s Global Head of Commercial

CEO Deanna White noted that the company’s recent business development announcements with Palantir, Wheels Up, and BETA Technologies all reflect progress across its core objectives.

Inside the Wheels Up Deal: The Contract That Proved SurfOS Sells

For years, the open question around the Surf Air Mobility model was whether its software would sell beyond its own operations. In June, SRFM closed the deal that answered it.

Wheels Up is one of the world’s largest private aviation companies. On June 25, it signed on as the launch customer for Enterprise BrokerOS under a two-year firm agreement that includes $8 million in subscription fees, with an option for a third year, for total potential software revenue of up to $12 million.

The product it bought was already proving itself. BrokerOS has been commercially live since December 2025 with 29 independent brokers enrolled, and early internal results showed 32% more bookings for top brokers, 57% faster quote-to-close, and 40% more payments processed on-platform in Q1 2026 versus Q1 2025. The same engine powered Surf On Demand to its best quarter since inception, with revenue up 77% year over year to $10.1 million and revenue per flight up 38%.

The moat behind it is structural. SRFM holds an exclusive five-year agreement with Palantir Technologies for the configuration and sale of Foundry and AIP-powered software to the Part 135 regional aviation market. Palantir is one of the largest non-insider shareholders, and Shawn Pelsinger, the former Palantir executive who helped architect Skywise with Airbus, joined the board in October 2025 and was just elected Chairman, effective July 24, 2026.

“We are pleased with our first quarter Adjusted EBITDA results, which exceeded our expectations. The progress we’ve made across our business has positioned us to improve our annual 2026 Adjusted EBITDA guidance by 40% while maintaining our full year revenue guidance. The efficiencies gained within our core businesses in the first quarter are a clear indication of the value that SurfOS and our partnership with Palantir delivers.” – Deanna White, CEO, Surf Air Mobility

And the balance sheet is being rebuilt to match. On July 1, the company refinanced a roughly $46.9 million senior secured convertible note into a new $16.9 million convertible note due 2027 and a new $30 million non-convertible senior secured term note due 2028. In plain English: less potential dilution ahead for shareholders.

The BETA ALIA in Surf Air livery. Through its strategic partnership with BETA Technologies, SRFMholds a firm order for 25 all-electric aircraft, with options for up to 75 more, and eliminated up to $100 million in planned capital expenditure from its prior electrification program. A new demonstration program launched in Hawaii on June 26, with Hawaiian Airlines supporting evaluation activities, testing regional cargo operations ahead of the company’s plan to become the first Part 135 operator to commercialize electric passenger flights for scheduled service and on-demand charter.

The Market Opportunity Is Almost Too Big to Ignore

Surf Air Mobility already operates at real scale. In the first quarter of 2026 alone, the company flew 65,376 scheduled passengers across 12,503 scheduled departures and 11,061 scheduled flight hours,while its Surf On Demand private charter arm completed 832 flights, all at a 96% controllable completion factor.

The runway ahead is far larger. The regional air mobility market is projected to reach $75 to $115 billion globally by 2035, and the eVTOL aircraft market is forecast to grow from over $5 billion in 2026 to more than $216 billion by 2035.

Membership in the FAA-sponsored CAAT Consortium adds another lane, giving SRFM potential access to FAA-funded research programs, eligibility to respond to task orders reserved for consortium members, and a seat in the working groups shaping future solicitations. The consortium is a national initiative between the Texas A&M University System and the Federal Aviation Administration, built to integrate electric aircraft, autonomous systems, and advanced aviation technology into the national airspace.

Management

Deanna White – Chief Executive Officer – Leads the Los Angeles-based air mobility platform through its transition into a software and electrification company. Under her leadership, SRFM beat its Q1 2026 Adjusted EBITDA guidance, improved its full year outlook by roughly 40%, expanded the Palantir partnership, landed Wheels Up as the first enterprise SurfOS customer, and refinanced its convertible debt to reduce future dilution.

Shawn Pelsinger – Chairman of the Board, effective July 24, 2026 – Former Palantir executive who helped architect Skywise with Airbus. Joined the Surf Air Mobility board in October 2025 and was just elected Chairman.

NEWS

Jul 1, 2026 Surf Air Mobility Announces Debt Financing Transactions Designed to Reduce Future Dilution

Jun 29, 2026 Palantir and Surf Air Mobility Expand Partnership

Jun 25, 2026 Surf Air Mobility Announces Wheels Up as Launch Customer for Enterprise BrokerOS

Jun 24, 2026 Schedule 13G Shows Palantir Holds a 7.4% Stake in Surf Air Mobility

Jun 16, 2026 Surf Air Mobility Showcases AIP-Enabled BrokerOS at Palantir AIPCon 10

As always, remember to do your own research.

‍

This email is sponsored content. It is provided for informational purposes only and does not constitute investment advice, an offer to sell, or a solicitation of an offer to buy any security. Market figures and company data are drawn from public filings and press releases. Readers should conduct their own research and consult a licensed financial advisor before making any investment decision.

Remember to do your own research.

SINCERELY,

DISCLAIMER

MicroCapAlerts.io is owned by Dedicated Investors, LLC who is a publisher (the “Publisher”) of favorable information (the “Information”) about publicly traded companies (collectively the “Issuers”) listed on the NASDAQ Stock Exchange (“NASDAQ”), New York Stock Exchange (“NYSE”) and the OTC Markets is a paid advertisement. The Publisher lists its specific compensation at the bottom of this Disclaimer.

The Persons who pay us (“Paying Party”) to publish the Information and their affiliates may hold and control a significant amount of the public float and believe that if potential investors receive favorable information about the Issuers, investors will purchase the Issuers’ shares, including the shares that the Paying Party wants to sell.  The Information is neither a solicitation to buy nor an offer to sell securities. The Information is not intended to be used as a source of information for making an investment decision. The Information is not intended and should not be used for trading or investment purposes.  

Because the Publisher is paid to disseminate the Information to the public, the Publisher is required by the securities laws, including Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose certain information to you regarding its compensation, including the nature and amount of compensation. The Paying Party and its affiliates may engage in buying and selling of the Issuers’ securities before, during and after the Publication of the Information.

The Information provides de minimis information about the Issuers and is only a brief favorable snapshot of the Issuers subject to the Information. The Information consists of only positive content and does not include any negative information about the Issuers whatsoever; accordingly, you should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. The Publisher is not liable for your use of the Information or any success or failure that is directly or indirectly related to your use of the Information, including misinformation, omissions, errors or delays in providing or updating the Information, or for any actions taken by third parties in reliance upon the Information.

The Publisher is not objective or independent, and its publishing of the Information involves actual and material conflicts of interest, including: (i) the Publisher is paid to publish favorable information about the Issuers; (ii) the Publisher does not publish negative information because it is not paid to do so; and (iii) the Publisher is paid to publish the (favorable) Information about the Issuers advising others, including you, to purchase the Issuers’ securities; and while doing so, the Paying Party may plan to sell their shares of the Issuers.

The Information published by the Publisher may recommend that investors buy the Issuers’ shares while the Paying Party and/or their affiliates sell their shares of the Issuers. When the Paying Party sells their shares, the Issuers’ stock price may decline and thereby dramatically reduce the price at which investors can sell their shares. As such, investors who purchase the Issuers’ shares during the Publication of the Information will likely pay inflated prices. The Paying Party may sell the Issuers’ securities for less than the target prices set forth in the Information. The Paying Party and its affiliates may make substantial profits by selling their securities during the Publication of the Information while investors experience losses.  

The Publisher makes no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability, and disclaims, expressly and impliedly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the information is at your own risk.  The Information is provided “as is” without any warranties of any kind without limitation. The Publisher does not verify or confirm any portion of the Information and does not conduct any due diligence or research on any aspect of the Information, including the completeness, accuracy, truthfulness or reliability of the Information.  

Investors should not rely upon the Information for any purpose and should contact a licensed investment advisor and their legal advisor and review all documents about the Issuers with the assistance of such advisors, including documents publicly filed on www.sec.gov and http://www.OTCMarkets.com  to obtain information about the Issuers.

Before investing in any public company, you should conduct your own in-depth investigation with the assistance of your legal, tax and investment advisors of the Issuers’ financial condition, operations, management, products or services, trends in the industry, the Issuers’ trading history, short sale positions and risks that may be material to its business and other information you and your advisors deem material to an investment decision. This investigation should include, but not be limited to, a review of available public sources and information you receive directly from http://www.OTCMarkets.com  and www.sec.gov.

The Publisher is not and does not act in the capacity of any of the following and is not qualified to do so; as such, you should not construe the Publisher’s activities as involving any of the following:

▪ An independent advisor or consultant;

▪ Providing investment advice or acting in the capacity of an investment adviser or engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;

▪ Broker-dealer activities or acting in the capacity of a registered representative or broker;

▪ Stock picker;

▪ Securities trading expert;

▪ Securities researcher or analyst;  

▪ Financial planner or financial planning;

▪ Provider of stock recommendations;

▪ Provider of advice about buying and selling or holding recommendations as to specific securities; or

▪ Making an offer or sale of securities or solicitation to purchase securities.

An investment in the Issuers involves a high degree of risk and uncertainties and may be subject to extreme volume and price volatility, especially during the Publication of the Information.  Favorable past performance of the Issuers does not guarantee future results. If you purchase the securities of the Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Issuers include but are not limited to the risks stated below.

▪ The Information is not a solicitation or recommendation to buy, sell or hold securities, and the Publisher does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. The Publisher conducts no due diligence or investigation of the Information or the Issuers and does not receive any verification from any party regarding the Information.

▪ If the Publisher publishes any percentage gain of the Issuers’ share from the previous day’s close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.  

▪ The Information may contain statements that Issuers’ stock price has increased over a certain period of time, which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon such information in your analysis of the present or future potential of the Issuers or its securities.

▪ The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Issuers’ future stock price or future financial performance.

▪ You may encounter difficulties determining what, if any, portions of the Information are material or nonmaterial, making it all the more imperative that you conduct your own independent investigation of the Issuers and its securities with the assistance of your legal, tax and financial advisor.  

▪ If the Information states that its securities are consistent with the future economic trends or even if your independent research indicates as such, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that Publisher is unable to predict; (c) human and social factors may outweigh future economic trends that Publisher states may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in such economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of fully new circumstances and situations in which uncertainty becomes reality rather than of predictive economic quality; or (f) if the trends involve a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.

▪ The Information contains forward-looking statements, i.e., statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as expects, will, anticipates, and estimates; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Issuers with the assistance of your lawyer, tax advisor and investment advisor as well as any such forward-looking statements. Any forward-looking statements made in the Information are limited to the time period in which they are made, and the Publisher does not undertake to update forward-looking statements that may change at any time.  

▪ The Information is presented only as a brief snapshot of the Issuers and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Issuers and its securities and to consult your financial, legal or other advisor(s) and avail yourself of the filings and information that may be accessed at www.sec.gov or other electronic medium, including: (a) reviewing Information and Disclosure Statements and unaudited financial reports filed with the www.otcmarkets.com; (b) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (c) investment guides at www.sec.gov and www.finra.org.  You should always be concerned that the Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative signs at otcmarkets.com. You should only invest with the assistance of your attorney, lawyer and tax advisor after they have conducted exhaustive due diligence on the particular Issuer and its trading activity.

▪ The Publisher may hire third-party service providers and stock promoters to electronically disseminate live news about the Issuers, yet the Publisher has no control over the content of and does not verify the information that these service providers publish.

The Publisher or its officers, directors, owners, managers, affiliates and control persons were paid to publish the Information about the issuers identified below:

Name of Issuer: 3rd party on behalf of Surf Air Mobility Inc

Amount of Cash Compensation: twenty thousand usd

Period of Publication of Information: One day campaign beginning and ending on July sixteenth twenty twenty six

Previous Compensation: One or more partners of Dedicated Investors LLC has been previously compensated one hundred ninety one thousand five hundred usd on behalf of Surf Air Mobility Inc.

Where Information is Published: MicroCapAlerts.io Website, Email Campaign, SMS Campaign, Social Media including but not limited to: Youtube, X, Tiktok, Instagram, Stock Twits, Reddit, Discord.

By reading the Information and visiting the Platform, you agree you have not relied on the Information and agree to indemnify, defend and hold the Publisher harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to your receipt of the Information without limitation.

Notes

1 https://www.businesswire.com/news/home/20260511482704/en/Surf-Air-Mobility-Reports-First-Quarter-2026-Financial-Results-Outperforming-Adjusted-EBITDA-Guidance

2 https://finance.yahoo.com/technology/articles/palantir-surf-air-mobility-expand-105900123.html

3 https://www.corporatejetinvestor.com/news/surf-air-palantir/

4 https://investors.surfair.com/news/news-details/2026/Surf-Air-Mobility-Announces-Wheels-Up-as-Launch-Customer-for-Enterprise-BrokerOS/default.aspx

5 https://www.businesswire.com/news/home/20260513531116/en/Surf-Air-Mobility-Joins-FAA-Sponsored-Center-for-Advanced-Aviation-Technologies-Consortium

6 https://www.mckinsey.com/industries/aerospace-and-defense/our-insights/short-haul-flying-redefined-the-promise-of-regional-air-mobility

7 https://www.precedenceresearch.com/evtol-aircraft-market

8 https://www.surfair.com/

9 https://investors.surfair.com/

‍

‍

Categories
Report

KSCP

*Sponsored by Knightscope, Inc.

Knightscope Reports Q1 2026 Revenue Up 106% to $6.0 Million; Gross Margin Turns Positive for the First Time

Knightscope Announces Nearly $4 Million in New and Recurring Contracts Across Eight Verticals

Knightscope Expands Workforce Again as the Nation’s First Autonomous Security Force Scales Toward Its GSX 2026 Debut

READ THE INVESTOR PRESENTATION HERE

________________________

Hello Everyone,

This next company operates in one of the most critical and consistently broken sectors in America today.

Physical security and autonomous technology are two of the most powerful forces reshaping modern infrastructure. The convergence of AI, robotics, and managed services is creating enormous opportunities, not just for technology companies, but for investors who recognize a structural shift before the rest of the market does.

The physical security industry is enormous, deeply entrenched, and almost entirely untouched by real innovation. The US market alone is estimated at $230 billion. It spans every sector of the American economy, from government, healthcare, education, retail, critical infrastructure, and residential communities, and it is built on recurring, non-discretionary spending. Security is not optional. It is a legal requirement, a liability concern, and an operational necessity.

Yet despite all of that scale, the industry is broken. Businesses pay between $220,000 and $570,000 annually just to cover a single location around the clock. Police coverage runs $438,000 to $1.3 million per year for a single 24/7 post. More than 90% of security alerts are non-actionable without a human in the loop. And the average corporate security chief manages 8 to 12 vendors, none of them accountable to each other.

The result is a structural reset. IT security consolidated to the managed-service model twenty years ago and minted a generation of category leaders. Physical security never had that moment. One company is building it.

The company we are looking at today is constructing something that has never existed before in America. A fully managed security service that combines autonomous robots, AI-driven software, real-time monitoring, and licensed armed and unarmed security agents into one integrated operation. A system that deters, detects, and responds to threats in real time. A platform that owns the outcome for its clients, not just sells them another piece of a broken puzzle.

That company is Knightscope, Inc. (NASDAQ: KSCP). And the first quarter of 2026 was the moment its plan clicked into place.

Q1 revenue came in at $6.0 million, up 106% year over year, with gross margin positive for the first time in company history and roughly 70% of revenue now recurring. With the Event Risk acquisition closed, all four operational pillars of the Autonomous Security Force, autonomous machines, advanced software, real-time monitoring, and licensed security agents, are finally under one roof. KSCP is converting its structural advantages into real, accelerating revenue.

KSCP has some major catalysts in play right now:

● Q1 2026 Revenue Up 106%, Gross Margin Positive for the First Time: Revenue reached $6.0 million, up from $2.9 million a year earlier. Service revenue grew 98% to $4.2 million. Product revenue climbed 128% to $1.8 million. Gross margin hit positive 8% of revenue versus a gross loss in the prior-year period. Even on a like-for-like pro forma basis, revenue grew 39%. This is not a pre-revenue concept. The inflection is on the books.

● Nearly $4 Million in Fresh Bookings Across Eight Verticals: In May, Knightscopeannounced approximately $3.8 million in new and recurring contracts led by critical infrastructure, including a major California county government, the federal government, a US national laboratory, regional transit, aviation and port authorities, Fortune 500 pharmaceutical and healthcare organizations, and national retail brands.

● Event Risk Acquisition Closed, All Four Pillars in Place: The approximately $18 million acquisition added licensed armed and unarmed guarding and executive protection with Fortune 1000 relationships, consistent double-digit growth, and strong retention. Every guarding contract becomes a deployment channel for autonomous machines. Guards become Augmented Security Agents. Static posts get replaced by robots over time.

● Workforce Growth Continues, With Equity for the Frontline: After quadrupling its workforce to over 400 in March, Knightscope announced another significant expansion in July, adding 136 employees across security, supervisory, and operations roles with equity inducement grants. In an industry historically plagued by extreme turnover, building an ownership culture is a genuine competitive differentiator.

● Roughly 70% Recurring Revenue Across 434 Clients in 42 States: $4.2 million of the $6.0 million in Q1 revenue was recurring service revenue, supported by approximately 10,000 machines and agents in the network and more than 4.4 million autonomous hours logged since 2015. Managed services businesses are valued on exactly this mix.

● The All-New K7 Flagship Debuts at GSX 2026: The K7 Autonomous Security Robot is built for environments no camera or human post can match: miles of fence lines, logistics yards, solar farms, critical infrastructure, and defense installations. A public waitlist is open, limited series production is expected to begin deployment in the second half of 2026, and the Autonomous Security Force debuts at GSX 2026 in Atlanta, September 14-16, Booth 3905.

● Carnegie Mellon Collaboration Feeding the K7: Under a five-year letter agreement, five graduate students from Carnegie Mellon’s Robotics Institute are already building an advanced AI feature for the K7, and Knightscope is making its National Security Robotics Lab in Silicon Valley available to the university.

● Multi-Billion-Dollar Market Opportunity: The $230 billion US physical security market spans public safety and government ($57B), retail and hospitality ($38B), critical infrastructure ($37B), enterprise ($34B), education ($21B), transit and smart cities ($20B), residential and community security ($18B), and healthcare ($7B).

● Validated by Palantir Technologies: Knightscope is targeting FedRAMP High and DoD Impact Level 5 certification in partnership with Palantir’s (NASDAQ: PLTR) FedStart program. Palantir does not partner with companies that are not ready to operate inside mission-critical environments.

‍Knightscope Expands Workforce to Support Growing Security Services Operations; Company Approves Inducement Grants Under Nasdaq Rule 5635(c)(4)

SUNNYVALE, Calif., July 9, 2026 (BUSINESS WIRE)

Knightscope, Inc. (NASDAQ: KSCP), the security technology company building the Nation’s First Autonomous Security Force, announced a significant expansion of its workforce to support its growing technology-enabled security services operations.

In connection with these new hires, the Compensation Committee of the Company’s Board of Directors approved equity awards to 136 employees as inducement grants material to their employment with the Company. In the aggregate, the inducement grants consist of options to purchase 732,644 shares of the Company’s common stock at an exercise price of $2.04 per share, granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The awards were issued across security, supervisory, and operations roles supporting the Company’s expanding base of recurring-revenue deployments nationwide. Twenty-five percent of the shares subject to each award vest on the first anniversary of the grant date, with the remainder vesting in equal monthly installments over a three-year period.

“The frontline is where our reputation is won or lost every single day and is a critical component of our Autonomous Security Force. Extending ownership to the agents and supervisors doing that work aligns everyone behind the same thing our clients care about: quality that holds up over the long term, shift after shift,” said William Santana Li, Chairman and Chief Executive Officer, Knightscope, Inc.

Professionals interested in joining the Knightscope team at headquarters or in the field can apply at www.knightscope.com/careers, where numerous positions are open as the Force continues to grow.

Inside the Event Risk Acquisition: The Deal That Completed the Force

For years, the missing piece of the Knightscope model was licensed guarding: the capability that wins RFPs, satisfies regulators, and puts trained humans on-site when judgment is required. In February, KSCP closed the deal that filled it.

Event Risk is a nationwide provider of armed and unarmed security guarding services and executive protection. It built its reputation on disciplined execution: consistent double-digit growth, strong client retention, and established service relationships with Fortune 1000 companies, national brands, and high-profile individuals. It entered 2026 with significant contracted revenue, positive EBITDA, and expectations of continued double-digit growth, before counting any synergies.

The deal structure is worth noting, because it was built to protect shareholders. Knightscopeacquired 100% of Event Risk for approximately $18 million in cash and stock at closing, plus deferred and contingent consideration tied to post-closing performance, including earn-outs based on 2026 revenue and gross margin thresholds and capped revenue-share payments through 2031. In plain English: a meaningful portion of the price only gets paid if the business delivers.

The strategic payoff was immediate. In roughly one month of combined operations, the newly formed Knightscope Security Force contributed approximately $2.4 million in Q1 revenue,added a second operating segment, and gave KSCP the structural capability to contract as the licensed provider, deploy autonomous systems, monitor centrally, and execute response under one accountable operating structure. Management expects the acquisition to support triple-digit revenue growth in 2026.

Running it is Eric J. Rose, Event Risk’s founder, a US Marine with specialized anti-terrorism experience and prior service as lead trainer for US Navy SEALs, with senior leadership roles at Pinkerton, Apple, and Madison Square Garden. Rose now serves as President of the operation, which is transitioning to the Knightscope Security Force brand during 2026.

“Event Risk has built its reputation through disciplined execution and trusted service delivery. We are fundamentally building a better team, combining disciplined execution with advanced technology, to deliver exceptional value to our clients.” – Eric J. Rose, President, Knightscope Security Force

And the logic behind buying a guarding company in the first place is the same logic behind the whole strategy. Every security RFP in America is written for guards and cameras. Guards get Knightscope in the door. Trust gets earned. Then robots and software replace static posts one at a time, and the economics of the contract transform. Guards are not the destination. They are the deployment catalyst for autonomy.

The all-new K1 Capsule (left) is a next generation emergency communication device designed for environments that need a more compact and versatile form factor, with AI analytics, 360-degree video, and two-way communication. The all-new K1 Super Tower (right) takes the blue light concept to an entirely new level, a commanding, highly visible emergency communication presence available in 7, 14, and 21 foot versions. Both are integrated with the AI-driven Signals software platform and slated for limited production in the second half of 2026.

The Market Opportunity Is Almost Too Big to Ignore

Knightscope is targeting an estimated $230 billion total addressable market. This is not a niche opportunity. Security is not discretionary spending. It is a legal requirement, a liability concern, and a fundamental operational necessity for almost every organization in the country.

Across its top five Security Force clients alone, the company estimates more than $850 million in annual security spend, of which Knightscope holds less than 2% today. Add a retrofit path for the 200,000+ legacy blue-light towers in the US installed base, and the land-and-expand runway is measured in years, not quarters. Security is a recurring societal problem that requires a recurring solution.

Management

William Santana Li – Chairman and CEO – Founded Knightscope in 2013 after more than a decade at Ford Motor Company and leadership roles in automotive and security-focused ventures including GreenLeaf LLC, later part of LKQ Corporation (NASDAQ: LKQ). Focused on using advanced technology to help make the United States the safest country in the world.

Eric J. Rose – President, Security Force – Founder of Event Risk. US Marine with specialized anti-terrorism experience and prior service as lead trainer for US Navy SEALs, with senior leadership roles at Pinkerton, Apple, and Madison Square Garden. Leads the licensed guarding and executive protection operations of the Autonomous Security Force.

NEWS

Jul 9, 2026 Knightscope Expands Workforce to Support Growing Security Services Operations

May 19, 2026 Knightscope Announces Nearly $4 Million in New and Recurring Contracts

May 15, 2026 Knightscope Q1 Revenue Up 106% to $6M

Apr 15, 2026 Knightscope and Carnegie Mellon University Enter Into Letter Agreement

Mar 30, 2026 Knightscope Reports 2025 Results, Advances Autonomous Security Force

Mar 17, 2026 Knightscope Quadruples Workforce to Over 400 Strong

Mar 3, 2026 Knightscope Acquires Event Risk to Accelerate Autonomous Security Force Strategy

Feb 5, 2026 Knightscope Retains Lake Street to Support Growth Through Acquisitions

Nov 13, 2025 Knightscope Unveils the All-New K7 Autonomous Security Robot

Notes

1 https://ir.knightscope.com/hubfs/KSCP%20Investor%20Deck%20%20-%2007.09.26.pdf

2 https://www.businesswire.com/news/home/20260515717960/en/

3 https://www.businesswire.com/news/home/20260519157402/en/Knightscope-Announces-Nearly-$4-Million-in-New-and-Recurring-Contracts

4 https://www.businesswire.com/news/home/20260302323510/en/Knightscope-Acquires-Event-Risk-to-Accelerate-Autonomous-Security-Force-Strategy

5 https://www.businesswire.com/news/home/20260317081578/en/

6 https://ir.knightscope.com/news-events/press-releases

7 https://www.businesswire.com/news/home/20251113250459/en/

8 https://www.businesswire.com/news/home/20260415011296/en/Knightscope-and-Carnegie-Mellon-University-Enter-Into-Letter-Agreement

9 https://knightscope.com

SINCERELY,

DISCLAIMER

MicroCapAlerts.io is owned by Dedicated Investors, LLC who is a publisher (the “Publisher”) of favorable information (the “Information”) about publicly traded companies (collectively the “Issuers”) listed on the NASDAQ Stock Exchange (“NASDAQ”), New York Stock Exchange (“NYSE”) and the OTC Markets is a paid advertisement. The Publisher lists its specific compensation at the bottom of this Disclaimer.

The Persons who pay us (“Paying Party”) to publish the Information and their affiliates may hold and control a significant amount of the public float and believe that if potential investors receive favorable information about the Issuers, investors will purchase the Issuers’ shares, including the shares that the Paying Party wants to sell.  The Information is neither a solicitation to buy nor an offer to sell securities. The Information is not intended to be used as a source of information for making an investment decision. The Information is not intended and should not be used for trading or investment purposes.  

Because the Publisher is paid to disseminate the Information to the public, the Publisher is required by the securities laws, including Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose certain information to you regarding its compensation, including the nature and amount of compensation. The Paying Party and its affiliates may engage in buying and selling of the Issuers’ securities before, during and after the Publication of the Information.

The Information provides de minimis information about the Issuers and is only a brief favorable snapshot of the Issuers subject to the Information. The Information consists of only positive content and does not include any negative information about the Issuers whatsoever; accordingly, you should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. The Publisher is not liable for your use of the Information or any success or failure that is directly or indirectly related to your use of the Information, including misinformation, omissions, errors or delays in providing or updating the Information, or for any actions taken by third parties in reliance upon the Information.

The Publisher is not objective or independent, and its publishing of the Information involves actual and material conflicts of interest, including: (i) the Publisher is paid to publish favorable information about the Issuers; (ii) the Publisher does not publish negative information because it is not paid to do so; and (iii) the Publisher is paid to publish the (favorable) Information about the Issuers advising others, including you, to purchase the Issuers’ securities; and while doing so, the Paying Party may plan to sell their shares of the Issuers.

The Information published by the Publisher may recommend that investors buy the Issuers’ shares while the Paying Party and/or their affiliates sell their shares of the Issuers. When the Paying Party sells their shares, the Issuers’ stock price may decline and thereby dramatically reduce the price at which investors can sell their shares. As such, investors who purchase the Issuers’ shares during the Publication of the Information will likely pay inflated prices. The Paying Party may sell the Issuers’ securities for less than the target prices set forth in the Information. The Paying Party and its affiliates may make substantial profits by selling their securities during the Publication of the Information while investors experience losses.  

The Publisher makes no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability, and disclaims, expressly and impliedly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the information is at your own risk.  The Information is provided “as is” without any warranties of any kind without limitation. The Publisher does not verify or confirm any portion of the Information and does not conduct any due diligence or research on any aspect of the Information, including the completeness, accuracy, truthfulness or reliability of the Information.  

Investors should not rely upon the Information for any purpose and should contact a licensed investment advisor and their legal advisor and review all documents about the Issuers with the assistance of such advisors, including documents publicly filed on www.sec.gov and http://www.OTCMarkets.com  to obtain information about the Issuers.

Before investing in any public company, you should conduct your own in-depth investigation with the assistance of your legal, tax and investment advisors of the Issuers’ financial condition, operations, management, products or services, trends in the industry, the Issuers’ trading history, short sale positions and risks that may be material to its business and other information you and your advisors deem material to an investment decision. This investigation should include, but not be limited to, a review of available public sources and information you receive directly from http://www.OTCMarkets.com  and www.sec.gov.

The Publisher is not and does not act in the capacity of any of the following and is not qualified to do so; as such, you should not construe the Publisher’s activities as involving any of the following:

▪ An independent advisor or consultant;

▪ Providing investment advice or acting in the capacity of an investment adviser or engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;

▪ Broker-dealer activities or acting in the capacity of a registered representative or broker;

▪ Stock picker;

▪ Securities trading expert;

▪ Securities researcher or analyst;  

▪ Financial planner or financial planning;

▪ Provider of stock recommendations;

▪ Provider of advice about buying and selling or holding recommendations as to specific securities; or

▪ Making an offer or sale of securities or solicitation to purchase securities.

An investment in the Issuers involves a high degree of risk and uncertainties and may be subject to extreme volume and price volatility, especially during the Publication of the Information.  Favorable past performance of the Issuers does not guarantee future results. If you purchase the securities of the Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Issuers include but are not limited to the risks stated below.

▪ The Information is not a solicitation or recommendation to buy, sell or hold securities, and the Publisher does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. The Publisher conducts no due diligence or investigation of the Information or the Issuers and does not receive any verification from any party regarding the Information.

▪ If the Publisher publishes any percentage gain of the Issuers’ share from the previous day’s close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.  

▪ The Information may contain statements that Issuers’ stock price has increased over a certain period of time, which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon such information in your analysis of the present or future potential of the Issuers or its securities.

▪ The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Issuers’ future stock price or future financial performance.

▪ You may encounter difficulties determining what, if any, portions of the Information are material or nonmaterial, making it all the more imperative that you conduct your own independent investigation of the Issuers and its securities with the assistance of your legal, tax and financial advisor.  

▪ If the Information states that its securities are consistent with the future economic trends or even if your independent research indicates as such, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that Publisher is unable to predict; (c) human and social factors may outweigh future economic trends that Publisher states may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in such economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of fully new circumstances and situations in which uncertainty becomes reality rather than of predictive economic quality; or (f) if the trends involve a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.

▪ The Information contains forward-looking statements, i.e., statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as expects, will, anticipates, and estimates; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Issuers with the assistance of your lawyer, tax advisor and investment advisor as well as any such forward-looking statements. Any forward-looking statements made in the Information are limited to the time period in which they are made, and the Publisher does not undertake to update forward-looking statements that may change at any time.  

▪ The Information is presented only as a brief snapshot of the Issuers and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Issuers and its securities and to consult your financial, legal or other advisor(s) and avail yourself of the filings and information that may be accessed at www.sec.gov or other electronic medium, including: (a) reviewing Information and Disclosure Statements and unaudited financial reports filed with the www.otcmarkets.com; (b) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (c) investment guides at www.sec.gov and www.finra.org.  You should always be concerned that the Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative signs at otcmarkets.com. You should only invest with the assistance of your attorney, lawyer and tax advisor after they have conducted exhaustive due diligence on the particular Issuer and its trading activity.

▪ The Publisher may hire third-party service providers and stock promoters to electronically disseminate live news about the Issuers, yet the Publisher has no control over the content of and does not verify the information that these service providers publish.

The Publisher or its officers, directors, owners, managers, affiliates and control persons were paid to publish the Information about the issuers identified below:

Name of Issuer: Knightscope, Inc

Amount of Cash Compensation: twenty thousand usd

Period of Publication of Information: One day campaign beginning and ending on July fifteenth twenty twenty six

Previous Compensation: One or more partners of Dedicated Investors LLC has been previously compensated one hundred twenty thousand usd on behalf of Knightscope Inc.

Where Information is Published: MicroCapAlerts.io Website, Email Campaign, SMS Campaign, Social Media including but not limited to: Youtube, X, Tiktok, Instagram, Stock Twits, Reddit, Discord.

By reading the Information and visiting the Platform, you agree you have not relied on the Information and agree to indemnify, defend and hold the Publisher harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to your receipt of the Information without limitation.

Categories
Report

FEED

*Sponsored by ENvue Medical, Inc

A leading nonprofit health system running 12 hospitals across Virginia and North Carolina recently made the platform its standardized protocol for bedside feeding tube placement, extending the relationship through 2028  

The ENvue System is FDA 510(k) cleared and currently in use at hospitals across the United States

According to Yahoo, FEED on has just over 6M Shares

_________________________

Hello Everyone,

We have something for you to keep an eye on for today’s session. Research this one right away.

The real story is in the float. According to Yahoo, FEED on has just over 6M Shares.

5 Catalysts to pay attention to for ENvue Medical, Inc. (Nasdaq: FEED) for today:

1. Three Distinct Platforms in One Company: ENvue Medical isn’t a one-product story—it runs three separate device platforms targeting feeding tube placement, chronic pain, and hospital-acquired infections.

2. GPS-Style Feeding Tube Navigation: The ENvue System uses electromagnetic field technology and built-in sensors to create a real-time body map, showing providers exactly where a feeding tube is traveling—like GPS for the inside of the body.

3. A Genuine Patient-Safety Problem: Misplaced feeding tubes can enter the airway instead of the digestive tract, with consequences that can be severe or even fatal. The system’s red-arrow alerts warn when the tube approaches the airway.

4. FDA-Cleared and Already in Hospitals: The ENvue System is FDA 510(k) cleared and currently in use at hospitals across the United States.

5. Becoming Standard of Care: A leading nonprofit health system running 12 hospitals across Virginia and North Carolina recently made the platform its standardized protocol for bedside feeding tube placement, extending the relationship through 2028.

Across the United States, hospitals perform more than 13M feeding tube placements every year — yet a staggering 85% of those procedures are still performed blindly, without any real-time visual guidance, forcing clinicians to wait on radiology confirmation before a single drop of nutrition can reach a patient.

(FEED) built its platform specifically to fix that problem — and this week, independent peer-reviewed science confirmed that it works.

A study just published in the official journal of the American Association of Critical Care Nurses showed the ENvue™ Navigation Platform saved over 350 nursing hours in year one, cut repeat imaging by 20%, and reduced hospital-acquired aspiration pneumonia by 20% across a multi-hospital health system.

Those aren’t projections. They are real-world, independently documented clinical outcomes.

The commercial story around this name has been developing fast — and there are now even more reasons to have FEED on your radar this morning.

The company operates two distinct technology platforms that together address a wide range of clinical and home-care needs.

The ENvue™ Navigation Platform is a minimally invasive electromagnetic navigation system that assists clinicians in placing nasoenteral feeding tubes at the bedside with real-time visual guidance.

The system is FDA 510(k) cleared for adult use and is now commercially deployed across 40 U.S. hospitals, generating recurring consumable revenue as clinicians integrate it into their daily workflow.

The company’s second platform, the Acoustic Therapeutic Platform, includes PainShield® and UroShield® — devices utilizing proprietary low-intensity surface acoustic wave (SAW) technology designed for pain reduction, biofilm disruption, and bacterial colonization prevention in home and clinical settings.

UroShield recently secured reimbursement approval in the UK, adding an international revenue channel through distributor Peak Medical.

Leadership is anchored by Doron Besser, MD, Chief Executive Officer, with Marc Waldman serving as VP of Commercial — bringing over 35 years of medical device commercial leadership to the role. David Johnson serves as Chairman of the Board.

ENvue Medical (NASDAQ: FEED) Just Unlocked the Recurring Revenue Story Investors Have Been Waiting For

ENvue Medical has just introduced Ask Oscar™, an AI-powered training platform that goes straight at the single biggest bottleneck standing between any medical technology and full-scale hospital adoption: training. And the way management is framing it, this isn’t a side feature — it’s the layer that changes the entire economics of how ENvue scales.

Here’s the problem Ask Oscar was built to solve. Hospitals are stretched thin, clinicians rotate shifts constantly, and every new competency requirement means pulling a specialist on-site to train nurses and dietitians in person. That bottleneck has quietly capped how fast even great medical technology can spread through a health system. Ask Oscar removes it entirely by letting clinicians train independently, on their own schedule, with the platform monitoring procedural performance in real time, catching deviations, and delivering immediate corrective coaching — no educator required to be standing in the room.

That alone would be a meaningful operational upgrade. But the real signal for investors is what CEO Doron Besser is saying about the business model underneath it: Ask Oscar is expected to be commercially available within the coming months across ENvue’s entire installed hospital base, and management is positioning it as a scalable, recurring revenue stream layered directly on top of the existing Navigation Platform footprint. In other words, ENvue isn’t just selling more hardware into hospitals — it’s building a second revenue engine on top of the customers it’s already won.

And Ask Oscar isn’t a standalone side project. It’s built on ENvue’s existing navigation and training infrastructure, and every session run through the platform generates data that feeds an intelligence layer designed to support the Company’s broader roadmap — including ENvue Drive, its patent-pending robotic-assisted feeding tube placement initiative. Management describes the foundation here as extending well beyond training itself, toward future intelligent guidance and advanced procedural assistance across the entire ENvue ecosystem.

This launch also doesn’t happen in a vacuum — it lands right behind a landmark independent, peer-reviewed study published in Critical Care Nurse that put hard numbers behind the ENvue Navigation Platform’s clinical impact: zero lung placements across 531 consecutive procedures, a 67% reduction in ventilator-associated pneumonia, a staggering 4,320% increase in post-pyloric feeding access, more than 350 nursing hours freed annually, and over $1.5 million in annual cost avoidance within a single health system. That’s the kind of validation that turns a sales conversation into a standard-of-care decision — and now ENvue is pairing that clinical credibility with an AI layer designed to make adoption faster and stickier across every account it touches.

Put simply: ENvue just gave hospitals a faster way to say yes, and gave itself a new way to get paid for it.

Burn ICU Expansion Signals Growing Clinical Versatility

Two days after that publication, on June 5, 2026, FEED announced that a major U.S. academic health network has expanded its use of the ENvue™ Navigation Platform into its American Burn Association-verified burn intensive care unit — marking the second deployment within the same health system.

Burn ICU patients represent one of the most clinically challenging and vulnerable populations in hospital medicine. Feeding tube placement in this setting carries elevated risk, and the decision to expand an existing platform relationship into the burn ICU — rather than simply maintaining current deployments — signals a level of institutional trust that goes well beyond standard contract renewals.

CEO Doron Besser, MD, addressed it directly: “We believe that this health network’s decision to bring the ENvue Navigation Platform into their burn ICU speaks directly to the clinical versatility of our platform and institutional trust that we have earned with this network.”

The fact that this expansion occurred within a health system already using the platform — and came just days after peer-reviewed clinical results from a multi-hospital Inova deployment — suggests a pattern of deepening institutional commitment rather than one-off adoption.

Commercial Momentum: The Bigger Picture

Before these two most recent developments, FEED had already been building a compelling commercial foundation:

On May 12, 2026, FEED announced that its ENvue™ Navigation Platform was adopted as the standardized protocol for bedside feeding tube placement across a 12-hospital integrated non-pro-fit health network in Virginia and North Carolina — a three-year renewal running through 2028. Standardized protocol status means the platform is embedded directly into clinical workflow as the method of care, driving consistent utilization across the network rather than simply being available for optional use.

On May 7, 2026, FEED locked in a three-year GPO purchasing agreement renewal tied to one of the largest non-pro-fit health systems in the U.S. — encompassing more than 90 hospitals across 17 states.

Any participating hospital can now move directly to adoption without navigating lengthy value analysis committee approvals. CEO Doron Besser, MD, stated the arrangement makes the platform “one clinical decision away from adoption” at any participating facility.

FEED also holds two recently issued USPTO Notices of Allowance — one covering a next-generation feeding tube combining electromagnetic navigation with a distal-tip camera, and a second covering SAW technology applied to transdermal compound delivery — broadening the IP portfolio into pain management, neurology, and inflammation applications.

NEWS

June 9, 2026
ENvue Medical Launches AI Training Platform Establishing Artificial Intelligence Foundation for Robotic Feeding Tube Navigation
June 5, 2026
ENvue Medical Expands into Burn Intensive Care Unit at Major Academic Health Network
June 3, 2026
ENvue Medical Announces Publication of Landmark Independent Study Highlighting Significant Safety, Time-, and Cost-Saving Benefits of ENvue Navigation Platform in Multi-Hospital System
May 19, 2026
ENvue Medical to Showcase ENvue™ Navigation Platform at AACN NTI 2026
May 12, 2026
ENvue Medical Secures Three-Year Contract Renewal at 12-Hospital U.S. Health Network as the ENvue™ Navigation Platform Becomes Standard of Care
May 8, 2026
ENvue Medical Adds to Intellectual Property Portfolio by Securing USPTO Notice of Allowance for Ultrasound-Enhanced Cannabinoid Drug Delivery Technology
May 7, 2026
ENvue Medical Secures Three-Year Purchasing Agreement Renewal with the Group Purchasing Organization (GPO) for One of the Largest Health Systems in the U.S. Operating Over 90 Hospitals
April 16, 2026
ENvue Issues Stockholder Letter & Provides Corporate Update‍
March 24, 2026
ENvue Medical Expands Presence within a Major Michigan Health System and Grows U.S. Hospital Footprint to 39

MANAGEMENT

Doron Besser, M.D.

Chief Executive Officer

Doron Besser is the CEO of ENvue Medical and NanoVibronix (Nasdaq: NAOV), overseeing the integration of the two divisions: electromagnetic navigation for enteral feeding (ENvue) and non-invasive therapeutic devices for pain and urology (NanoVibronix).

Doron is continuing the advancement and commercialization of ENvue navigation system for enteral feeding, leading global strategy, clinical education, commercialization in the U.S. and ROW, and expansion into new applications including pediatrics and vascular access.

Prior to managing both divisions, Doron co-founded and managed ENvizion Medical and Swing Medical, a private equity investment fund. Doron guided ENvizion Medical from concept to FDA clearance, built U.S. clinical adoption, and launched the ENvue system into hospitals as a next-generation navigation platform.

Doron also co-founded and led NutriSeal, a company focused on preventing nasoenteral-induced gastric reflux and ventilator-associated pneumonia (VAP). Prior to NutriSeal, Doron served as CEO of Angioslide Ltd., a company specializing in innovative, cost effective angioplasty products. Doron guided the company through its infancy stages, which included complicated animal and human trials, to FDA clearance, CE approval and initial market penetration in Europe and the US. Doron also served as VP of Clinical and Marketing and VP of Business Development at super Dimension, a leader in minimally-invasive pulmonology devices. Doron helped lead super Dimension from its inception, serving on the core team that identified opportunities within the pulmonology market. In 2012, Covidien acquired superDimension for ~$300 million.

As a seasoned entrepreneur, Doron specializes in identifying breakthrough technologies and developing them throughout all product development phases, including international sales and marketing activities.

He holds a Doctor of Medicine degree from Munich’s Ludwig-Maximilians University.

Zenya Gorlik

VP R&D

Zenya Gorlik is a seasoned software expert with over 20 years of experience in developing large-scale multidisciplinary projects in military and medical industries from geographic information systems for intelligence to MRI medical devices and beyond.  He specializes in managing projects end-to-end from concept to delivery.

Before joining ENvue Medical in 2021, Zenya served as senior software engineer and team leader at Camtek, ImageSat International, and Aspect Imaging, as software consultant at CodeValue, and more.

He holds a BA in mathematics and computer science from Haifa University, and is certified as a systems analysis engineer by the Technion Institute of Technology.

Anat Hofshi, PhD

VP Clinical Affairs & Product

With a great belief in technologies that can improve patient safety, Dr. Hofshi joined ENvue Medical in 2016 to lead the clinical activities and trials required to finalize the R&D phase and to commercialize the ENvue system in the US. Dr. Hofshi brings outstanding ability to interconnect between different disciplines areas and a high level of practical and hands-on skills.

Previous to her joining ENvue, Dr. Hofshi, served as a Project Leader at B.G. Guard and Carmel StemSense, startup companies in the field of Diabetics.

Dr. Hofshi holds a B.S.c in Biotechnology and Food engineering and a PhD from the Department of Physiology and Biophysics, Technion Institute, specializing in Electrophysiology, Stem Cells and Cardiovascular Regenerative Medicine. Dr. Hofshi received many awards and honors for her scientific accomplishments (Wolf, etc.).

SINCERELY,

DISCLAIMER

MicroCapAlerts.io is owned by Dedicated Investors, LLC who is a publisher (the “Publisher”) of favorable information (the “Information”) about publicly traded companies (collectively the “Issuers”) listed on the NASDAQ Stock Exchange (“NASDAQ”), New York Stock Exchange (“NYSE”) and the OTC Markets is a paid advertisement. The Publisher lists its specific compensation at the bottom of this Disclaimer.

The Persons who pay us (“Paying Party”) to publish the Information and their affiliates may hold and control a significant amount of the public float and believe that if potential investors receive favorable information about the Issuers, investors will purchase the Issuers’ shares, including the shares that the Paying Party wants to sell.  The Information is neither a solicitation to buy nor an offer to sell securities. The Information is not intended to be used as a source of information for making an investment decision. The Information is not intended and should not be used for trading or investment purposes.  

Because the Publisher is paid to disseminate the Information to the public, the Publisher is required by the securities laws, including Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose certain information to you regarding its compensation, including the nature and amount of compensation. The Paying Party and its affiliates may engage in buying and selling of the Issuers’ securities before, during and after the Publication of the Information.

The Information provides de minimis information about the Issuers and is only a brief favorable snapshot of the Issuers subject to the Information. The Information consists of only positive content and does not include any negative information about the Issuers whatsoever; accordingly, you should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. The Publisher is not liable for your use of the Information or any success or failure that is directly or indirectly related to your use of the Information, including misinformation, omissions, errors or delays in providing or updating the Information, or for any actions taken by third parties in reliance upon the Information.

The Publisher is not objective or independent, and its publishing of the Information involves actual and material conflicts of interest, including: (i) the Publisher is paid to publish favorable information about the Issuers; (ii) the Publisher does not publish negative information because it is not paid to do so; and (iii) the Publisher is paid to publish the (favorable) Information about the Issuers advising others, including you, to purchase the Issuers’ securities; and while doing so, the Paying Party may plan to sell their shares of the Issuers.

The Information published by the Publisher may recommend that investors buy the Issuers’ shares while the Paying Party and/or their affiliates sell their shares of the Issuers. When the Paying Party sells their shares, the Issuers’ stock price may decline and thereby dramatically reduce the price at which investors can sell their shares. As such, investors who purchase the Issuers’ shares during the Publication of the Information will likely pay inflated prices. The Paying Party may sell the Issuers’ securities for less than the target prices set forth in the Information. The Paying Party and its affiliates may make substantial profits by selling their securities during the Publication of the Information while investors experience losses.  

The Publisher makes no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability, and disclaims, expressly and impliedly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the information is at your own risk.  The Information is provided “as is” without any warranties of any kind without limitation. The Publisher does not verify or confirm any portion of the Information and does not conduct any due diligence or research on any aspect of the Information, including the completeness, accuracy, truthfulness or reliability of the Information.  

Investors should not rely upon the Information for any purpose and should contact a licensed investment advisor and their legal advisor and review all documents about the Issuers with the assistance of such advisors, including documents publicly filed on www.sec.gov and http://www.OTCMarkets.com  to obtain information about the Issuers.

Before investing in any public company, you should conduct your own in-depth investigation with the assistance of your legal, tax and investment advisors of the Issuers’ financial condition, operations, management, products or services, trends in the industry, the Issuers’ trading history, short sale positions and risks that may be material to its business and other information you and your advisors deem material to an investment decision. This investigation should include, but not be limited to, a review of available public sources and information you receive directly from http://www.OTCMarkets.com  and www.sec.gov.

The Publisher is not and does not act in the capacity of any of the following and is not qualified to do so; as such, you should not construe the Publisher’s activities as involving any of the following:

▪ An independent advisor or consultant;

▪ Providing investment advice or acting in the capacity of an investment adviser or engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;

▪ Broker-dealer activities or acting in the capacity of a registered representative or broker;

▪ Stock picker;

▪ Securities trading expert;

▪ Securities researcher or analyst;  

▪ Financial planner or financial planning;

▪ Provider of stock recommendations;

▪ Provider of advice about buying and selling or holding recommendations as to specific securities; or

▪ Making an offer or sale of securities or solicitation to purchase securities.

An investment in the Issuers involves a high degree of risk and uncertainties and may be subject to extreme volume and price volatility, especially during the Publication of the Information.  Favorable past performance of the Issuers does not guarantee future results. If you purchase the securities of the Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Issuers include but are not limited to the risks stated below.

▪ The Information is not a solicitation or recommendation to buy, sell or hold securities, and the Publisher does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. The Publisher conducts no due diligence or investigation of the Information or the Issuers and does not receive any verification from any party regarding the Information.

▪ If the Publisher publishes any percentage gain of the Issuers’ share from the previous day’s close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.  

▪ The Information may contain statements that Issuers’ stock price has increased over a certain period of time, which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon such information in your analysis of the present or future potential of the Issuers or its securities.

▪ The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Issuers’ future stock price or future financial performance.

▪ You may encounter difficulties determining what, if any, portions of the Information are material or nonmaterial, making it all the more imperative that you conduct your own independent investigation of the Issuers and its securities with the assistance of your legal, tax and financial advisor.  

▪ If the Information states that its securities are consistent with the future economic trends or even if your independent research indicates as such, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that Publisher is unable to predict; (c) human and social factors may outweigh future economic trends that Publisher states may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in such economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of fully new circumstances and situations in which uncertainty becomes reality rather than of predictive economic quality; or (f) if the trends involve a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.

▪ The Information contains forward-looking statements, i.e., statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as expects, will, anticipates, and estimates; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Issuers with the assistance of your lawyer, tax advisor and investment advisor as well as any such forward-looking statements. Any forward-looking statements made in the Information are limited to the time period in which they are made, and the Publisher does not undertake to update forward-looking statements that may change at any time.  

▪ The Information is presented only as a brief snapshot of the Issuers and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Issuers and its securities and to consult your financial, legal or other advisor(s) and avail yourself of the filings and information that may be accessed at www.sec.gov or other electronic medium, including: (a) reviewing Information and Disclosure Statements and unaudited financial reports filed with the www.otcmarkets.com; (b) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (c) investment guides at www.sec.gov and www.finra.org.  You should always be concerned that the Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative signs at otcmarkets.com. You should only invest with the assistance of your attorney, lawyer and tax advisor after they have conducted exhaustive due diligence on the particular Issuer and its trading activity.

▪ The Publisher may hire third-party service providers and stock promoters to electronically disseminate live news about the Issuers, yet the Publisher has no control over the content of and does not verify the information that these service providers publish.

The Publisher or its officers, directors, owners, managers, affiliates and control persons were paid to publish the Information about the issuers identified below:

Name of Issuer: ENvue Medical, Inc

Amount of Cash Compensation: fifteen thousand usd

Period of Publication of Information: One day campaign beginning and ending on July ninth twenty twenty six

Where Information is Published: MicroCapAlerts.io Website, Email Campaign, SMS Campaign, Social Media including but not limited to: Youtube, X, Tiktok, Instagram, Stock Twits, Reddit, Discord.

By reading the Information and visiting the Platform, you agree you have not relied on the Information and agree to indemnify, defend and hold the Publisher harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to your receipt of the Information without limitation.

Categories
Report

AEC

*Sponsored by Anfield Energy Inc

Anfield Energy Delivers Strong First-Half 2026 Momentum with Exceptional PEA Economics and Clear Path to Near-Term Production

Utah Legislators to Tour Anfield Energy’s Velvet-Wood Critical Minerals Project

Read the Investor Presentation HERE

_________________________

Hello Everyone,

The uranium sector is heating up and today we are putting a name on your radar that checks multiple boxes at once. Micro-cap market cap. Domestic uranium positioning. Operational progress. Improving fundamentals. This is the kind of convergence we get excited about. Meet Anfield Energy.

Anfield Energy (NASDAQ: AEC) is a U.S.-focused uranium and vanadium development company operating a hub-and-spoke production model built around domestic energy security. With a micro-cap market cap under $100 million, a recently secured mining fleet, improving year-over-year earnings, and technical signals beginning to fire, AEC sits at the intersection of a surging macro theme and early-stage operational momentum.

Nuclear energy is back in the spotlight and this time it is not a short-lived trend. Governments around the world are racing to secure reliable, carbon-free electricity as demand surges from AI data centers, electrification initiatives, and energy security priorities. That demand runs straight through uranium, and companies with assets inside North America have quickly become some of the most watched names in the space.

Anfield Energy is one of those companies. AEC has been quietly building out a U.S.-based uranium production hub using a hub-and-spoke development model, positioning itself directly inside the domestic supply chain narrative. The company holds a large uranium and vanadium asset portfolio and has been making deliberate moves to advance its production strategy.

Earlier this month, AEC announced it secured a key mining fleet, a concrete operational step that many small-cap resource companies never reach. The pieces are starting to line up for those watching this space closely.

THE SETUP: AEC combines exposure to one of the most powerful energy macro themes in the market right now. The company just secured a mining fleet, reported improved year-over-year earnings, and is showing early technical signs of a turnaround after a prolonged pullback.

4 Explosive Catalysts Driving AEC Into Our Focus

1. U.S. Uranium Supply Chain Positioning: Anfield Energy has built its entire strategy around becoming a domestic uranium production hub. As governments push hard for energy independence and nuclear expansion, companies with U.S.-based uranium assets are sitting exactly where attention is flowing. AEC is not chasing this theme from the outside. It is built for it.

2. Mining Fleet Secured: Earlier this month, AEC announced it had secured a key mining fleet to advance its U.S. uranium production strategy. This is not a press release about future intentions. This is an operational step that puts the company closer to actual production activity. In the small-cap resource world, milestones like this matter and the market tends to notice.

3. Improving Year-Over-Year Earnings: AEC reported meaningful earnings improvement in its most recent quarter compared to the same period last year. For a micro-cap company in development mode, showing forward progress on the financial side builds credibility and gives an additional fundamental reason to pay attention beyond just the sector story.

4. Micro-Cap Structure with Outsized Move Potential: With a market capitalization under $100 million, AEC sits in the zone where sector momentum can translate quickly. Small-cap resource companies in hot sectors can move quickly when attention builds.

Nuclear Power Is Back and Uranium Demand Is Going One Direction

Nuclear energy has re-entered the conversation as a serious, scalable solution to growing global electricity demand. Countries across North America, Europe, and Asia are extending reactor lifetimes, planning new builds, and actively working to secure uranium supply. The push is being driven by a combination of energy security concerns, carbon reduction goals, and the explosive growth of power-hungry AI infrastructure. Data centers alone are projected to dramatically increase electricity consumption over the coming years, and nuclear is one of the only sources capable of delivering reliable baseload power at scale.

Inside that macro environment, domestic uranium producers and developers have become priority targets for those who want direct exposure to the supply chain. AEC does not just benefit from uranium demand broadly. It benefits from the domestic-first energy policy push that is accelerating right now.

VIRAL FACTS: AEC holds a large uranium AND vanadium asset portfolio, giving it dual commodity exposure inside a single micro-cap structure. The company operates a hub-and-spoke development model specifically designed around future domestic U.S. production. AEC recently secured a key mining fleet, a concrete operational milestone. The company reported improved year-over-year earnings performance in its most recent quarter. Market cap sits under $100 million.

Anfield Energy: Building America’s Uranium Production Hub

Anfield Energy (NASDAQ: AEC) is a U.S.-focused uranium and vanadium development company working to build a domestic production hub designed for the energy security era. The company’s strategy centers on a hub-and-spoke model that consolidates its North American uranium and vanadium assets into a production-ready framework.

The company’s dual exposure to both uranium and vanadium sets it apart within the small-cap resource space. Vanadium, used in large-scale energy storage, adds an additional layer of commodity exposure beyond uranium alone. Anfield’s recent mining fleet acquisition signals that the company is moving beyond planning stages and pushing toward active operational progress, a key distinction in a sector where talk often outpaces action.

Fundamentals Moving in the Right Direction

Anfield Energy is led by a team focused on executing the company’s hub-and-spoke U.S. uranium development strategy. Management has continued to advance the company’s asset portfolio and push toward operational milestones, with the recent mining fleet acquisition representing a visible step forward in that execution.

On the financial side, AEC reported improved year-over-year earnings performance in its most recent quarter, showing meaningful progress compared to the same period last year. With a market capitalization under $100 million, the company remains a true micro-cap, which means it retains the kind of leverage to positive news flow and sector momentum that larger companies simply cannot offer. Improving fundamentals inside a micro-cap structure, in a hot sector, is a combination worth watching closely.

Domestic Uranium & Multiple Signals Converging

The uranium story is one of the most powerful macro stories in energy right now. Nuclear power demand is rising globally, domestic supply chains are being prioritized by policy, and AI-driven electricity consumption is adding another layer of urgency to the fuel demand picture. Anfield Energy sits directly inside that narrative with a portfolio of U.S.-based uranium and vanadium assets and a hub-and-spoke production model built for this environment.

Anfield Energy Delivers Strong First-Half 2026 Momentum with Exceptional PEA Economics and Clear Path to Near-Term Production

VANCOUVER, British Columbia, June 25, 2026 (GLOBE NEWSWIRE) — Anfield Energy Inc. (NASDAQ: AEC; TSX.V: AEC; FRANKFURT: 0AD) (“Anfield” or the “Company”) is pleased to provide a corporate update highlighting significant operational, permitting, and economic advancements in the first half of 2026. The Company is executing on its hub-and-spoke uranium and vanadium strategy, with a clear line of sight to production and robust project economics that position it for potentially substantial value creation.

Shootaring Canyon Mill Advancement

  • Point-of-Compliance Wells Installed: Successfully completed drilling of 8 new monitoring wells in May 2026 near proposed process ponds and the tailings management facility. This key milestone delivers essential baseline groundwater data ahead of resuming full operations at the fully permitted Shootaring Canyon Mill (“Shootaring”).
  • License Renewal & Refurbishment Progress: Ongoing engineering studies and refurbishment work at Shootaring are advancing well. The Company remains on track to convert the mill license from care-and-maintenance to operations, with production targeted for 2027.
  • Robust Economics Confirmed via Updated PEA (Filed June 2026): The updated Preliminary Economic Assessment1 (“PEA”) demonstrates the compelling value of Anfield’s integrated hub-and-spoke model. Highlights include:

– Pre-tax IRR of 106% and NPV of US$606 million (8% discount rate); post-tax IRR of 97% and NPV of US$533 million.– Rapid payback period of just 1.3 years on mine and mill capex.– Pre-production capex of approximately US$97 million (including contingency) over a 12-month period.– Average annual production over 15-year mine life: ~1.3 million pounds U₃O₈ and 6.4 million pounds V₂O₅ (peak year: 1.9M lbs U₃O₈ + 7.8M lbs V₂O₅).– Centralized processing at Shootaring (target capacity 1,000 tonnes per day) fed by Velvet-Wood, Slick Rock, and six West Slope mines (JD-6, JD-7, JD-8, JD-9, SR-11, SM-18).– Includes ~250,000 pounds of uranium from existing stockpiles near Shootaring.– Significant upside potential from the addition of 13 remaining U.S. Department of Energy (“DOE”) leases with minimal incremental capex, plus value-added processing technologies to improve grades and throughput.

Mining Project Advancement

  • Velvet-Wood Phase One Construction Completed (June 2026): Successfully finished Phase One, including topsoil stripping (set aside for reclamation), portal rehabilitation, temporary power installation, and road build-out. The project is now advancing to Phase Two, with production targeted by the end of 2026.
  • JD-8 Plan of Operations: Revised Plan of Operations submitted to DOE and Colorado Division of Reclamation, Mining and Safety (“DRMS”) in April 2026 following agency feedback.
  • SM-18 NOI & Drilling Program: In April 2026, the Company submitted the notice of intent to conduct a drilling program (“NOI”) at SM-18 designed to verify and potentially expand the existing mineral resources. Following an initial denial by DRMS and a subsequent denial of reconsideration, the Company has filed for a hearing with the relevant board. The Company is in discussions with DRMS and the Attorney General’s office to discuss a potential compromise. The Company continues to advance preparations for a comprehensive Plan of Operations.

Strategic Acquisitions & Operational Readiness

  • BRS Engineering Acquisition (May 2026): Completed acquisition of B.R.S. Inc. (“BRS Engineering”), providing dedicated in-house engineering expertise to accelerate Shootaring refurbishment and mining project development.
  • Underground Haul Truck Procurement (June 2026): Received underground haul truck from Young’s Machine (Utah manufacturer). This strengthens Anfield’s commitment to building a robust American supply chain for domestic uranium production.
  • Equipment Procurement Milestone (June 15, 2026): Additional key equipment procurement advances operational readiness for the hub-and-spoke production model.

U.S. Policy Support & Strategic Shareholder Backing

  • Supportive Federal Policy Environment: Anfield welcomes the U.S. government’s continued focus on domestic critical minerals and uranium supply chain security, including the January 2026 Section 232 proclamation on processed critical minerals. These measures reinforce the strategic importance of Anfield’s fully U.S.-based assets and near-term production capability.
  • Strategic Shareholder Alignment: Major shareholder, Uranium Energy Corp. (UEC) has increased its stake in Anfield, demonstrating strong confidence in the Company’s assets, team, and execution plan. This partnership provides valuable industry validation and potential synergies as Anfield advances toward production.

Management Commentary

“We are very proud of the substantial progress Anfield has delivered in the first half of 2026,” said Corey Dias, CEO of Anfield. “From completing critical mill infrastructure milestones and Phase One construction at Velvet-Wood, to securing in-house engineering capabilities and advancing our permitting pipeline, we are executing with precision. The updated PEA underscores the exceptional economics of our hub-and-spoke strategy—106% pre-tax IRR, US$606 million NPV, and a rapid 1.3-year payback—positioning Anfield for potentially significant value creation as we move toward production at Velvet-Wood by year-end 2026 and Shootaring in 2027. We are also encouraged by the supportive U.S. policy environment and the confidence shown by strategic shareholders. Anfield is well-positioned to contribute meaningfully to America’s domestic uranium and vanadium supply and the broader nuclear energy renaissance.”

Strategic Positioning

This progress aligns with Anfield’s hub-and-spoke strategy, leveraging the fully permitted Shootaring in Utah alongside its high-quality uranium-vanadium assets in Utah and Colorado. The Company remains focused on creating long-term shareholder value through efficient development, operational excellence, and contribution to U.S. energy security and the global transition to clean, carbon-free power.

NEWS


Utah Legislators to Tour Anfield Energy’s Velvet-Wood Critical Minerals Project

6 days ago

Anfield Energy Delivers Strong First-Half 2026 Momentum with Exceptional PEA Economics and Clear Path to Near-Term Production

Jun 25, 2026

Anfield Energy Files Its Updated Preliminary Economic Assessment Which Reflects its Robust Hub-And-Spoke Uranium and Vanadium Production Strategy

Jun 18, 2026

Anfield Energy Announces a Key Milestone in Equipment Procurement, Advancing the Company Towards Hub-and-Spoke Production

Jun 15, 2026

Anfield Energy Provides Operational Update on Shootaring Canyon Uranium Mill License Renewal and Refurbishment

Jun 8, 2026

Anfield Energy Inc. Completes Phase One Surface Construction at Velvet-Wood Project

Jun 1, 2026

Anfield Energy Completes Drilling of Monitoring Wells at Shootaring Canyon Mill and Slick Rock Mine Complex

May 13, 2026

Anfield Energy Demonstrates the Economic Viability of its Hub-And-Spoke Uranium and Vanadium Production Strategy Via Its Updated Preliminary Economic Assessment

May 4, 2026

Anfield Energy Submits Permit Amendment for JD-8 Mine Restart

Apr 8, 2026

Anfield Energy Inc. Submits Notice of Intent for Underground Drilling Program at SM-18 Uranium-Vanadium Project in Colorado, Advancing Fourth Mine in Hub-and-Spoke Strategy

Apr 2, 2026

‍

MANAGEMENT

‍

SINCERELY,

DISCLAIMER

MicroCapAlerts.io is owned by Dedicated Investors, LLC who is a publisher (the “Publisher”) of favorable information (the “Information”) about publicly traded companies (collectively the “Issuers”) listed on the NASDAQ Stock Exchange (“NASDAQ”), New York Stock Exchange (“NYSE”) and the OTC Markets is a paid advertisement. The Publisher lists its specific compensation at the bottom of this Disclaimer.

The Persons who pay us (“Paying Party”) to publish the Information and their affiliates may hold and control a significant amount of the public float and believe that if potential investors receive favorable information about the Issuers, investors will purchase the Issuers’ shares, including the shares that the Paying Party wants to sell.  The Information is neither a solicitation to buy nor an offer to sell securities. The Information is not intended to be used as a source of information for making an investment decision. The Information is not intended and should not be used for trading or investment purposes.  

Because the Publisher is paid to disseminate the Information to the public, the Publisher is required by the securities laws, including Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose certain information to you regarding its compensation, including the nature and amount of compensation. The Paying Party and its affiliates may engage in buying and selling of the Issuers’ securities before, during and after the Publication of the Information.

The Information provides de minimis information about the Issuers and is only a brief favorable snapshot of the Issuers subject to the Information. The Information consists of only positive content and does not include any negative information about the Issuers whatsoever; accordingly, you should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. The Publisher is not liable for your use of the Information or any success or failure that is directly or indirectly related to your use of the Information, including misinformation, omissions, errors or delays in providing or updating the Information, or for any actions taken by third parties in reliance upon the Information.

The Publisher is not objective or independent, and its publishing of the Information involves actual and material conflicts of interest, including: (i) the Publisher is paid to publish favorable information about the Issuers; (ii) the Publisher does not publish negative information because it is not paid to do so; and (iii) the Publisher is paid to publish the (favorable) Information about the Issuers advising others, including you, to purchase the Issuers’ securities; and while doing so, the Paying Party may plan to sell their shares of the Issuers.

The Information published by the Publisher may recommend that investors buy the Issuers’ shares while the Paying Party and/or their affiliates sell their shares of the Issuers. When the Paying Party sells their shares, the Issuers’ stock price may decline and thereby dramatically reduce the price at which investors can sell their shares. As such, investors who purchase the Issuers’ shares during the Publication of the Information will likely pay inflated prices. The Paying Party may sell the Issuers’ securities for less than the target prices set forth in the Information. The Paying Party and its affiliates may make substantial profits by selling their securities during the Publication of the Information while investors experience losses.  

The Publisher makes no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability, and disclaims, expressly and impliedly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the information is at your own risk.  The Information is provided “as is” without any warranties of any kind without limitation. The Publisher does not verify or confirm any portion of the Information and does not conduct any due diligence or research on any aspect of the Information, including the completeness, accuracy, truthfulness or reliability of the Information.  

Investors should not rely upon the Information for any purpose and should contact a licensed investment advisor and their legal advisor and review all documents about the Issuers with the assistance of such advisors, including documents publicly filed on www.sec.gov and http://www.OTCMarkets.com  to obtain information about the Issuers.

Before investing in any public company, you should conduct your own in-depth investigation with the assistance of your legal, tax and investment advisors of the Issuers’ financial condition, operations, management, products or services, trends in the industry, the Issuers’ trading history, short sale positions and risks that may be material to its business and other information you and your advisors deem material to an investment decision. This investigation should include, but not be limited to, a review of available public sources and information you receive directly from http://www.OTCMarkets.com  and www.sec.gov.

The Publisher is not and does not act in the capacity of any of the following and is not qualified to do so; as such, you should not construe the Publisher’s activities as involving any of the following:

▪ An independent advisor or consultant;

▪ Providing investment advice or acting in the capacity of an investment adviser or engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;

▪ Broker-dealer activities or acting in the capacity of a registered representative or broker;

▪ Stock picker;

▪ Securities trading expert;

▪ Securities researcher or analyst;  

▪ Financial planner or financial planning;

▪ Provider of stock recommendations;

▪ Provider of advice about buying and selling or holding recommendations as to specific securities; or

▪ Making an offer or sale of securities or solicitation to purchase securities.

An investment in the Issuers involves a high degree of risk and uncertainties and may be subject to extreme volume and price volatility, especially during the Publication of the Information.  Favorable past performance of the Issuers does not guarantee future results. If you purchase the securities of the Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Issuers include but are not limited to the risks stated below.

▪ The Information is not a solicitation or recommendation to buy, sell or hold securities, and the Publisher does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. The Publisher conducts no due diligence or investigation of the Information or the Issuers and does not receive any verification from any party regarding the Information.

▪ If the Publisher publishes any percentage gain of the Issuers’ share from the previous day’s close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.  

▪ The Information may contain statements that Issuers’ stock price has increased over a certain period of time, which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon such information in your analysis of the present or future potential of the Issuers or its securities.

▪ The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Issuers’ future stock price or future financial performance.

▪ You may encounter difficulties determining what, if any, portions of the Information are material or nonmaterial, making it all the more imperative that you conduct your own independent investigation of the Issuers and its securities with the assistance of your legal, tax and financial advisor.  

▪ If the Information states that its securities are consistent with the future economic trends or even if your independent research indicates as such, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that Publisher is unable to predict; (c) human and social factors may outweigh future economic trends that Publisher states may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in such economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of fully new circumstances and situations in which uncertainty becomes reality rather than of predictive economic quality; or (f) if the trends involve a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.

▪ The Information contains forward-looking statements, i.e., statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as expects, will, anticipates, and estimates; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Issuers with the assistance of your lawyer, tax advisor and investment advisor as well as any such forward-looking statements. Any forward-looking statements made in the Information are limited to the time period in which they are made, and the Publisher does not undertake to update forward-looking statements that may change at any time.  

▪ The Information is presented only as a brief snapshot of the Issuers and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Issuers and its securities and to consult your financial, legal or other advisor(s) and avail yourself of the filings and information that may be accessed at www.sec.gov or other electronic medium, including: (a) reviewing Information and Disclosure Statements and unaudited financial reports filed with the www.otcmarkets.com; (b) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (c) investment guides at www.sec.gov and www.finra.org.  You should always be concerned that the Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative signs at otcmarkets.com. You should only invest with the assistance of your attorney, lawyer and tax advisor after they have conducted exhaustive due diligence on the particular Issuer and its trading activity.

▪ The Publisher may hire third-party service providers and stock promoters to electronically disseminate live news about the Issuers, yet the Publisher has no control over the content of and does not verify the information that these service providers publish.

The Publisher or its officers, directors, owners, managers, affiliates and control persons were paid to publish the Information about the issuers identified below:

Name of Issuer: Anfield Energy, Inc

Amount of Cash Compensation: fifteen thousand usd

Period of Publication of Information: One day campaign beginning and ending on July seventh twenty twenty six

Where Information is Published: MicroCapAlerts.io Website, Email Campaign, SMS Campaign, Social Media including but not limited to: Youtube, X, Tiktok, Instagram, Stock Twits, Reddit, Discord.

By reading the Information and visiting the Platform, you agree you have not relied on the Information and agree to indemnify, defend and hold the Publisher harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to your receipt of the Information without limitation.

Categories
Report

ONCY

*Issuer Sponsored Content by Oncolytics Biotech, Inc

Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer

Pelareorep: A First-in-Class dsRNA Immunotherapy with FDA Pivotal Alignment Delivering 3–4x Survival Gains in Multiple GI Cancers

ONCY has multiple FDA Fast Track Designations, clinical validation in 1,200+ patients

Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches

READ THE INVESTOR PRESENTATION HERE

_________________________

Hello Everyone,

We are back with another exciting situation to look at for today’s session. This one has seen a lot of activity over the last moth or so and the buzz has been building.

Put ONCY on your radar immediately.

ONCY is hovering around that critical $1 level right now and the company has a lot of incentive to be on the other side of a buck.

The clinical-stage biotech behind pelareorep just secured FDA alignment on a pivotal registrational trial in metastatic anal cancer — a development that fundamentally changes the regulatory conversation around this company. Pair that with some of the more striking durability numbers seen in GI oncology recently, and ONCY is quietly building a case that’s harder to dismiss.

With multiple FDA Fast Track Designations, clinical validation in 1,200+ patients, and a registration-focused development strategy in colorectal and anal cancers, pelareorep is positioned as a differentiated immunotherapy platform targeting some of the largest and most underserved opportunities in oncology

The FDA Milestone That Changes the Math

In April 2026, Oncolytics reached alignment with the FDA on a registrational trial design for pelareorep in squamous cell anal cancer. This isn’t just a procedural checkbox — it’s a defined pathway toward potential approval.

The trial structure includes:

  • A single randomized study capable of supporting both accelerated and full approval
  • Pelareorep combined with a checkpoint inhibitor
  • Second-line and beyond SCAC patients
  • Approximately 80–100 participants
  • Primary endpoints centered on objective response rate and duration of response
  • Expected initiation in the second half of 2026

Late-stage anal cancer remains an area with no firmly established standard of care, which creates real space for a therapy producing durable responses.

The Colorectal Data That’s Getting Attention

The numbers coming out of ONCY’s colorectal cancer program are what initially put the company on the radar for many biotech watchers. In KRAS-mutant MSS metastatic colorectal cancer — historically one of the most resistant tumor types — pelareorep’s combination approach has posted results well above historical baselines:

  • 19.5-month median duration of response — compared to a typical 4–6 months
  • 33% response rate — versus a historical range of 6–11%
  • 27-month median overall survival — more than double the usual 11–13 month benchmark
  • 16.6-month progression-free survival — against a historical 5–7 month range

These aren’t marginal improvements. The durability gap between pelareorep’s data and standard-of-care history is wide enough to warrant serious attention.

Why the Platform Matters

The underlying science gives some context for why the data looks the way it does. Most GI tumors are immunologically “cold” — the immune system essentially fails to recognize them as threats, which is a core reason checkpoint inhibitors alone have underperformed in colorectal and pancreatic settings.

Pelareorep is an intravenously delivered dsRNA immunotherapy designed to work around that problem. It selectively replicates inside tumor cells, triggers immunogenic cell death, and appears to remodel the tumor microenvironment in ways that make checkpoint inhibitors more effective. The result is a potential “cold to hot” tumor conversion — activating both innate and adaptive immune responses in cancers that have historically resisted them.

CEO Jared Kelly has described the ambition as building pelareorep into a “backbone immunotherapy” across multiple cancer types, which is a bold framing — but the multi-indication data is at least beginning to support the thesis.

The Market Opportunity

The indications ONCY is targeting aren’t small. The global colorectal cancer therapeutics market is estimated around $20 billion, with the specific second-line KRAS-mutant MSS segment representing a potential $3–5 billion annual opportunity given how few effective options currently exist. Pancreatic cancer adds another multi-billion-dollar layer, and the anal cancer market is projected to expand significantly over the next decade.

For a company trading under a dollar, the gap between current valuation and addressable opportunity is notable.

What to Watch

Execution is the variable that matters most from here. The key milestones on the horizon include the anticipated trial launch in anal cancer, further data updates from the colorectal program, and any partnership or collaboration developments that could accelerate the pipeline.

ONCY carries the risk profile inherent to any clinical-stage biotech — regulatory outcomes are never certain, and early data doesn’t guarantee late-stage success. But the combination of FDA alignment, multi-indication durability data, Fast Track designations, and a sub-dollar entry point creates the kind of asymmetric setup that tends to attract attention in the small-cap biotech space.

The story is still being written. But the recent chapters have been more interesting than most.

Pipeline

Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches

Early results from solid tumor model support additional studies in pancreatic and colorectal cancer models; full dataset planned for presentation later in 2026

SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) — Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, today announced initial data from a preclinical study evaluating pelareorep in combination with RAS inhibitor modalities in a solid tumor model, which demonstrate evidence of greater anti-tumor activity in combination than with the individual approaches alone. Pelareorep is an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes.

Based on these findings, the Company is planning additional studies in models of pancreatic ductal adenocarcinoma (“PDAC”) and colorectal cancer (“CRC”) designed to further evaluate the combinations’ effects on immune activation, tumor response durability, and time-to-resistance. The ongoing work includes evaluations of pelareorep in combination with KRAS G12C inhibitors, pan-RAS inhibitors, and additional next-generation RAS pathway-targeting agents in RAS-mutated tumor models.

“We believe these initial findings further support pelareorep’s potential to serve as an immune-priming backbone for next-generation targeted therapies,” said Jared Kelly, Chief Executive Officer of Oncolytics. “RAS-mutated tumors, particularly pancreatic and colorectal cancers, remain among the most difficult cancers to treat due to intrinsic immune resistance and the emergence of therapeutic resistance over time. These preclinical results support further study of the combinations’ anti-tumor and immune effects, including in models designed to assess durability and time-to-resistance.”

Mr. Kelly continued, “Importantly, we believe this strategy may ultimately represent a potentially important area for further investigation in pancreatic cancer, where nearly all tumors harbor RAS pathway alterations and where patients continue to face extremely limited treatment options. The potential synergy observed in previous PDAC clinical studies and preclinical RAS-targeted modalities reinforces our belief that pelareorep may play an important role in future combination strategies designed to improve the durability of targeted therapies.”

Full results from the initial preclinical studies are expected to be presented in the fall or winter of 2026.

‍

NEWS


Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

Jun 16, 2026

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer

Jun 2, 2026

Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches

Jun 1, 2026

From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story

May 26, 2026

Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors

May 22, 2026

Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer

May 4, 2026

Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study

Apr 27, 2026

Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer

Apr 6, 2026

Oncolytics Biotech® Completes Domicile Change to the United States

Apr 1, 2026

The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology

Mar 19, 2026

‍

MANAGEMENT

Jared Kelly

Chief Executive Officer & Director

Jared Kelly is an accomplished lawyer and executive with a distinguished career in corporate law, particularly within the biotechnology sector. Mr. Kelly recently served as head of legal and corporate strategy at Ambrx and played a central role in its $2 billion sale to Johnson & Johnson. He has managed numerous transactions in the biotech space for companies at various stages of development. After leaving Ambrx, he has served as an advisor to multiple public and private drug development and pharmaceutical companies. Prior to becoming a biotech executive, Mr. Kelly was a sought-after public company lawyer who began his career with Kirkland & Ellis LLP, where he represented various public companies in securities offerings, IPOs and merger transactions. He also served as a partner at Lowenstein Sandler LLP, where his practice focused on representing biotechnology companies in financing transactions, mergers and acquisitions, and other complex transactions. Mr. Kelly received his J.D. and an LL.M. in Securities and Financial Regulation from Georgetown University Law Center, where he was the recipient of multiple honors and fellowships, including the Lane Evans Fellowship and Decrane Scholarship.

Kirk Look, CA, MSJ

Chief Financial Officer

Kirk Look is a Chartered Accountant with more than twenty years of experience in accounting, finance, tax and treasury. Mr. Look joined Oncolytics as the Company’s Controller in April 2003 and assumed the role of Chief Financial Officer in November 2012. Prior to joining Oncolytics, from 2000 to April 2003, Mr. Look was Manager of Audit and Assurance Services with Ernst & Young LLP in Canada. From 1998 to the end of 1999, Mr. Look held the positions of Audit Manager and Senior Accountant at Ernst & Young LLP in Chile. Mr. Look has a Bachelor of Commerce from the University of Calgary and a Master of Science in Jurisprudence Law Degree from the Seton Hall Law School.

Thomas C. Heineman, MD, PhD

Chief Medical Officer

Prior to joining Oncolytics, Dr. Thomas Heineman was Senior Vice President and Head of Clinical Development at Denovo Biopharma. Prior to his time at Denovo, he served as Vice President and Head of Clinical Development at both Genocea Biosciences and Halozyme Therapeutics. At Halozyme, Dr. Heineman was also Head of Translational Medicine and oversaw clinical trials in indications such as breast and pancreatic cancer. Dr. Heineman’s experience further extends to big pharma and academia, as he previously worked as Senior Director, Global Clinical Research and Development at GlaxoSmithKline and as an Associate Professor at the Saint Louis University School of Medicine. Dr. Heineman has co-authored over 60 peer-reviewed publications and is board certified in Internal Medicine and Infectious Diseases. He completed his fellowship in Infectious Diseases at the National Institutes of Health and his internship and residency at the University of Maryland. Dr. Heineman earned his MD and PhD in Virology at the University of Chicago.

Allison Hagerman, PEng, PMP, MBT

Chief Technology Officer

A professional engineer focused on biotechnology, Allison Hagerman joined Oncolytics in 2010 and has been integral to the progress of its product development program ever since. Prior to being appointed as Vice President of Product Development, Ms. Hagerman was the Director, Manufacturing and Engineering from 2013-2017 and Project Manager from 2010-2013, during which time she led the process performance qualification for pelareorep drug substance. Ms. Hagerman is a Professional Engineer (P.Eng., APEGA) and Project Management Professional (PMP, PMI). She holds a Master of Biomedical Technology (MBT) degree from the University of Calgary, and B.Sc. degrees in both Chemical Engineering and Biological Sciences. She is an accomplished equestrian and spends her spare time on horseback.

SINCERELY,

DISCLAIMER

MicroCapAlerts.io is owned by Dedicated Investors, LLC who is a publisher (the “Publisher”) of favorable information (the “Information”) about publicly traded companies (collectively the “Issuers”) listed on the NASDAQ Stock Exchange (“NASDAQ”), New York Stock Exchange (“NYSE”) and the OTC Markets is a paid advertisement. The Publisher lists its specific compensation at the bottom of this Disclaimer.

The Persons who pay us (“Paying Party”) to publish the Information and their affiliates may hold and control a significant amount of the public float and believe that if potential investors receive favorable information about the Issuers, investors will purchase the Issuers’ shares, including the shares that the Paying Party wants to sell.  The Information is neither a solicitation to buy nor an offer to sell securities. The Information is not intended to be used as a source of information for making an investment decision. The Information is not intended and should not be used for trading or investment purposes.  

Because the Publisher is paid to disseminate the Information to the public, the Publisher is required by the securities laws, including Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose certain information to you regarding its compensation, including the nature and amount of compensation. The Paying Party and its affiliates may engage in buying and selling of the Issuers’ securities before, during and after the Publication of the Information.

The Information provides de minimis information about the Issuers and is only a brief favorable snapshot of the Issuers subject to the Information. The Information consists of only positive content and does not include any negative information about the Issuers whatsoever; accordingly, you should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. The Publisher is not liable for your use of the Information or any success or failure that is directly or indirectly related to your use of the Information, including misinformation, omissions, errors or delays in providing or updating the Information, or for any actions taken by third parties in reliance upon the Information.

The Publisher is not objective or independent, and its publishing of the Information involves actual and material conflicts of interest, including: (i) the Publisher is paid to publish favorable information about the Issuers; (ii) the Publisher does not publish negative information because it is not paid to do so; and (iii) the Publisher is paid to publish the (favorable) Information about the Issuers advising others, including you, to purchase the Issuers’ securities; and while doing so, the Paying Party may plan to sell their shares of the Issuers.

The Information published by the Publisher may recommend that investors buy the Issuers’ shares while the Paying Party and/or their affiliates sell their shares of the Issuers. When the Paying Party sells their shares, the Issuers’ stock price may decline and thereby dramatically reduce the price at which investors can sell their shares. As such, investors who purchase the Issuers’ shares during the Publication of the Information will likely pay inflated prices. The Paying Party may sell the Issuers’ securities for less than the target prices set forth in the Information. The Paying Party and its affiliates may make substantial profits by selling their securities during the Publication of the Information while investors experience losses.  

The Publisher makes no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability, and disclaims, expressly and impliedly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the information is at your own risk.  The Information is provided “as is” without any warranties of any kind without limitation. The Publisher does not verify or confirm any portion of the Information and does not conduct any due diligence or research on any aspect of the Information, including the completeness, accuracy, truthfulness or reliability of the Information.  

Investors should not rely upon the Information for any purpose and should contact a licensed investment advisor and their legal advisor and review all documents about the Issuers with the assistance of such advisors, including documents publicly filed on www.sec.gov and http://www.OTCMarkets.com  to obtain information about the Issuers.

Before investing in any public company, you should conduct your own in-depth investigation with the assistance of your legal, tax and investment advisors of the Issuers’ financial condition, operations, management, products or services, trends in the industry, the Issuers’ trading history, short sale positions and risks that may be material to its business and other information you and your advisors deem material to an investment decision. This investigation should include, but not be limited to, a review of available public sources and information you receive directly from http://www.OTCMarkets.com  and www.sec.gov.

The Publisher is not and does not act in the capacity of any of the following and is not qualified to do so; as such, you should not construe the Publisher’s activities as involving any of the following:

▪ An independent advisor or consultant;

▪ Providing investment advice or acting in the capacity of an investment adviser or engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;

▪ Broker-dealer activities or acting in the capacity of a registered representative or broker;

▪ Stock picker;

▪ Securities trading expert;

▪ Securities researcher or analyst;  

▪ Financial planner or financial planning;

▪ Provider of stock recommendations;

▪ Provider of advice about buying and selling or holding recommendations as to specific securities; or

▪ Making an offer or sale of securities or solicitation to purchase securities.

An investment in the Issuers involves a high degree of risk and uncertainties and may be subject to extreme volume and price volatility, especially during the Publication of the Information.  Favorable past performance of the Issuers does not guarantee future results. If you purchase the securities of the Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Issuers include but are not limited to the risks stated below.

▪ The Information is not a solicitation or recommendation to buy, sell or hold securities, and the Publisher does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. The Publisher conducts no due diligence or investigation of the Information or the Issuers and does not receive any verification from any party regarding the Information.

▪ If the Publisher publishes any percentage gain of the Issuers’ share from the previous day’s close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.  

▪ The Information may contain statements that Issuers’ stock price has increased over a certain period of time, which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon such information in your analysis of the present or future potential of the Issuers or its securities.

▪ The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Issuers’ future stock price or future financial performance.

▪ You may encounter difficulties determining what, if any, portions of the Information are material or nonmaterial, making it all the more imperative that you conduct your own independent investigation of the Issuers and its securities with the assistance of your legal, tax and financial advisor.  

▪ If the Information states that its securities are consistent with the future economic trends or even if your independent research indicates as such, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that Publisher is unable to predict; (c) human and social factors may outweigh future economic trends that Publisher states may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in such economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of fully new circumstances and situations in which uncertainty becomes reality rather than of predictive economic quality; or (f) if the trends involve a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.

▪ The Information contains forward-looking statements, i.e., statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as expects, will, anticipates, and estimates; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Issuers with the assistance of your lawyer, tax advisor and investment advisor as well as any such forward-looking statements. Any forward-looking statements made in the Information are limited to the time period in which they are made, and the Publisher does not undertake to update forward-looking statements that may change at any time.  

▪ The Information is presented only as a brief snapshot of the Issuers and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Issuers and its securities and to consult your financial, legal or other advisor(s) and avail yourself of the filings and information that may be accessed at www.sec.gov or other electronic medium, including: (a) reviewing Information and Disclosure Statements and unaudited financial reports filed with the www.otcmarkets.com; (b) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (c) investment guides at www.sec.gov and www.finra.org.  You should always be concerned that the Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative signs at otcmarkets.com. You should only invest with the assistance of your attorney, lawyer and tax advisor after they have conducted exhaustive due diligence on the particular Issuer and its trading activity.

▪ The Publisher may hire third-party service providers and stock promoters to electronically disseminate live news about the Issuers, yet the Publisher has no control over the content of and does not verify the information that these service providers publish.

The Publisher or its officers, directors, owners, managers, affiliates and control persons were paid to publish the Information about the issuers identified below:

Name of Issuer: Oncolytics Biotech, Inc

Amount of Cash Compensation: fifteen thousand usd

Period of Publication of Information: One day campaign beginning and ending on July sixth twenty twenty six

Previous Compensation: One or more partners of Dedicated Investors LLC has been previously compensated twenty thousand usd on behalf of Oncolytics Biotech, Inc.

Where Information is Published: MicroCapAlerts.io Website, Email Campaign, SMS Campaign, Social Media including but not limited to: Youtube, X, Tiktok, Instagram, Stock Twits, Reddit, Discord.

By reading the Information and visiting the Platform, you agree you have not relied on the Information and agree to indemnify, defend and hold the Publisher harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to your receipt of the Information without limitation.